

CITATION REPORT

List of articles citing

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

DOI: 10.1126/science.1099314
Science, 2004, 304, 1497-500.

Source: <https://exaly.com/paper-pdf/37580197/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2187	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. 2010 , 4, 178		12
2186	Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. 1994 , 20, 373		
2185	Molecular markers help characterize neuroendocrine lung tumors. 1996 , 62, 798-809; discussion 809-10		109
2184	Sun Tzu and the Art of BusinessSun Tzu and the Art of Business By McNeillyMark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. 1997 , 11, 129-130		1
2183	Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. 2003 , 61, 1191-5		87
2182	Receptor tyrosine kinases and inhibitors in lung cancer. 2004 , 4, 589-604		28
2181	[Predicting response to Iressa: unexpected mechanism]. 2004 , 20, 750-1		0
2180	High sensitivity EndoV mutation scanning through real-time ligase proofreading. 2004 , 32, e148		20
2179	Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. 2004 , 4, 569-83		5
2178	EGFR mutations and sensitivity to gefitinib. 2004 , 351, 1260-1; author reply 1260-1		65
2177	From bench to bedside and back again?. 2004 , 170, 1765, 1767		
2176	The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. 2004 , 1, 2-3		15
2175	Hereditary papillary renal carcinoma type I. 2004 , 4, 855-68		77
2174	Analysis of FDA Approved Anticancer Drugs Reveals the Future of Cancer Therapy. 2004 , 3, 1033-1040		65
2173	Cancer. A bull's eye for targeted lung cancer therapy. <i>Science</i> , 2004 , 304, 1458-61	33.3	74
2172	Oncogenic mutations of PIK3CA in human cancers. 2004 , 3, 1221-4		384
2171	Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. 2004 , 10, 8351-6		58

2170	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. 2004 , 64, 8816-20	404
2169	Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. 2004 , 10, 7311-7	61
2168	Twenty-five years of treating advanced NSCLC: what have we achieved?. 2004 , 15 Suppl 4, iv81-3	11
2167	Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture?. 2004 , 22, 3209-11	4
2166	Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. 2004 , 10, 7764-74	93
2165	An agenda for clinical trials: clinical trials in the genomic era. 2004 , 1, 468-70	16
2164	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. 2004 , 96, 1133-41	333
2163	Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. 2004 , 10, 8613-9	17
2162	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. 2004 , 10, 8195-203	458
2161	Molecular prognostication for soft tissue sarcomas: are we ready yet?. 2004 , 22, 4031-4	29
2160	Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. 2004 , 10, 7547-54	81
2159	The miracle of Iressa. 2004 , 9, 245-6	10
2158	Molecularly targeted therapy: have the floodgates opened?. 2004 , 9, 357-60	43
2157	Identification and validation of cell surface antigens for antibody targeting in oncology. 2004 , 11, 659-87	91
2156	Racial disparity of epidermal growth factor receptor expression in prostate cancer. 2004 , 22, 4725-9	77
2155	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). 2004 , 13, 3029-43	139
2154	Biomarkers of response to gefitinib in non-small-cell lung cancer. 2004 , 1, 66-7	5
2153	Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer. 2004 , 3, 1496-7	11

2152	Imatinib: Paradigm or Anomaly?. 2004 , 3, 831-833	11
2151	Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. 2004 , 10, 8594-602	131
2150	Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. 2004 , 10, 6522-7	71
2149	Aligning the stakeholders. 2004 , 5, 605-7	1
2148	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. 2004 , 1, 27-34	4
2147	Identification of Gefitinib Target of NSCLC EGFR Gene Mutation Expected to Shift Focus of Drug Development. 2004 , 26, 8-9	
2146	Genomic Instability in Cancer: Biological and Mathematical Approaches. 2004 , 3, 1079-1083	6
2145	Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. 2004 , 22, 4442-5	200
2144	Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. 2004 , 64, 7241-4	316
2143	Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. 2004 , 5, 1621-33	48
2142	Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. 2004 , 91, 1301-7	43
2141	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004 , 101, 13306-11	3659
2140	Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. 2004 , 91 Suppl 2, S1-2	15
2139	Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. 2004 , 34, 901-15	36
2138	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24	41
2137	Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?. 2004 , 96, 1117-9	34
2136	Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. 2004 , 64, 9101-4	105
2135	A molecular chink in the lung cancer armour. 2004 , 9, 426-7	

2134	The impact of systems approaches on biological problems in drug discovery. 2004 , 22, 1215-7	187
2133	Will tomorrow's medicines work for everyone?. 2004 , 36, S34-42	112
2132	Cancer genes and the pathways they control. 2004 , 10, 789-99	3175
2131	Creating incentives for genomic research to improve targeting of therapies. 2004 , 10, 1289-91	13
2130	No longer in the dark. 2004 , 4, 415-416	2
2129	Switching on kinases: oncogenic activation of BRAF and the PDGFR family. 2004 , 4, 718-27	142
2128	A vision for the National Cancer Program in the United States. 2004 , 4, 820-8	39
2127	Gefitinib--a novel targeted approach to treating cancer. 2004 , 4, 956-65	283
2126	Pharmacogenomics: bench to bedside. 2004 , 3, 739-48	220
2125	Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. 2004 , 3, 763-9	159
2124	Strategies to overcome resistance to targeted protein kinase inhibitors. 2004 , 3, 1001-10	276
2123	Development of TGF-beta signalling inhibitors for cancer therapy. 2004 , 3, 1011-22	452
2122	Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. 2004 , 5, 669-76	300
2121	Pharmacogenetics: ethical problems and solutions. 2004 , 5, 676-80	28
2120	Pharmacogenetics and drug development: the path to safer and more effective drugs. 2004 , 5, 645-56	233
2119	RNAi and HTS: exploring cancer by systematic loss-of-function. 2004 , 23, 8392-400	49
2118	DNA-microarray analysis of brain cancer: molecular classification for therapy. 2004 , 5, 782-92	166
2117	G1 cell-cycle control and cancer. 2004 , 432, 298-306	929

2116	Targeted cancer therapy. 2004 , 432, 294-7	834
2115	Astronomy: where are Procyon's quakes?. 2004 , 430, 29-30	10
2114	Cancer: understanding the target. 2004 , 430, 30	12
2113	Athletics: momentous sprint at the 2156 Olympics?. 2004 , 431, 525	54
2112	Lung cancer: intragenic ERBB2 kinase mutations in tumours. 2004 , 431, 525-6	655
2111	Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer. 2004 , 5, 331-2	
2110	2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004. 2004 , 6, 11-6	
2109	Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. 2004 , 6, 79-82	7
2108	Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer. 2004 , 6 Suppl 1, S6	
2107	Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. 2004 , 5, 411-5	68
2106	Molecular approach to breast cancer treatment. 2004 , 31, 6-13	59
2105	Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. 2004 , 31, 27-31	11
2104	Using germ-line genetic variation to investigate and treat cancer. 2004 , 9, 610-8	9
2103	The story of gefitinib, an EGFR kinase that works in lung cancer. 2004 , 9, 587	4
2102	Bioinformatics and cancer target discovery. 2004 , 9, 795-802	35
2101	Molecular targets and cancer therapeutics. 2004 , 9, 1042-4	
2100	Role of pathologists in the molecular targeted therapy of cancer. 2004 , 54, S342-S348	
2099	Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. 2004 , 6, 123-8	124

2098	Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. 2004 , 6 Suppl 1, S7-S19	29
2097	Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. 2004 , 6 Suppl 1, S24-9	38
2096	Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. 2004 , 6 Suppl 1, S30-4	15
2095	Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. 2004 , 6 Suppl 1, S35-42	8
2094	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. 2004 , 6 Suppl 1, S43-7	3
2093	Use of proteasome inhibition in the treatment of lung cancer. 2004 , 6 Suppl 2, S89-96	18
2092	Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. 2004 , 500, 267-80	58
2091	Chemotherapy in hormone refractory prostate cancer: where do we stand?. 2004 , 46, 709-11	5
2090	Apoptosis pathway-targeted drugs--from the bench to the clinic. 2004 , 1705, 53-66	29
2089	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. 2004 , 5, 525-31	82
2088	c-Src and cooperating partners in human cancer. 2004 , 6, 209-14	481
2087	The convergence of cancer prevention and therapy in early-phase clinical drug development. 2004 , 6, 321-6	41
2086	Somatic alterations in the human cancer genome. 2004 , 6, 433-8	128
2085	Targeting cell cycle and apoptosis for the treatment of human malignancies. 2004 , 16, 670-8	87
2084	Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. 2004 , 64, 8723-30	35
2083	Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. 2004 , 101, 1632-8	68
2082	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. 2004 , 101, 1733-44	7
2081	Role of pharmacogenomics in drug development. 2004 , 62, 86-96	6

2080	Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. 2004 , 8, 432-41	39
2079	A hot spot for protein kinase inhibitor sensitivity. 2004 , 11, 587-9	10
2078	Microscale protein expression profiling during disease evolution. 2004 , 1053, 279-90	9
2077	New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. 2004 , 6, 204-10	47
2076	The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. 2004 , 13, 1569-77	61
2075	Epidermal growth factor receptor inhibition strategies in oncology. 2004 , 11, 689-708	275
2074	Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. 2004 , 64, 9093-100	132
2073	An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. 2004 , 64, 9139-43	224
2072	Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. 2004 , 22, 3238-47	922
2071	Carcinomes pliomorphes : un dilemme diagnostic. 2004 , 24, 88-90	
2070	Adhœcarcinomes pulmonaires : un challenge pour la dœction prœce. 2004 , 24, 85-88	
2069	[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targeting]. 2004 , 21, 881-5	0
2068	[Prediction of response to tyrosine kinase epithelial cell growth factor receptor inhibitors: a major breakthrough in the treatment of non-small-cell lung cancer]. 2004 , 60, 252-3	
2067	Unraveling lung cancer biology by animal models and gene expression profiling. 2004 , 1, 25-30	
2066	Biomarkers in cancer management: a crucial bridge toward personalized medicine. 2004 , 1, 305-311	1
2065	Targeted therapies for cancer [from tamoxifen to gefitinib (Iressa)]. 2004 , 1, 411-416	2
2064	Network-targeted combination therapy: a new concept in cancer treatment. 2004 , 1, 425-433	12
2063	Population genetics for target identification. 2004 , 1, 69-74	10

2062	Program to improve cognitive functioning in patients with schizophrenia: reflections. 2004 , 72, 75-7	4
2061	Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. 2004 , 64, 2475-92	19
2060	Molecular markers and prostate cancer prognosis. 2004 , 3, 157-64	16
2059	Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. 2004 , 6 Suppl 1, S20-3	73
2058	Bronchoalveolar carcinoma: current treatment and future trends. 2004 , 6 Suppl 2, S75-9	3
2057	Translation research: from accurate diagnosis to appropriate treatment. 2004 , 2, 35	25
2056	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. 2004 , 64, 8919-23	1059
2055	[The pathologist and EGFR in 2004: I like you, nor do it]. 2004 , 24, 416-26	1
2054	Somatic mutations of EGFR in colorectal cancers and glioblastomas. 2004 , 351, 2883	255
2053	Méthodologie d'évaluation des thérapies ciblées dans les essais cliniques. perspectives d'avenir. 2004 , 60, 72-78	
2052	Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. 2004 , 7, 245-55	28
2051	Pharmacogenomics in cancer therapy: is host genome variability important?. 2004 , 25, 457-64	30
2050	Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. 2004 , 10, 481-6	251
2049	Beyond fast track for drug approvals. 2004 , 351, 501-5	41
2048	Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. <i>Science</i> , 2004 , 305, 1163-7	333 1400
2047	Technology platforms for pharmacogenomic diagnostic assays. 2004 , 3, 749-61	81
2046	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. 2004 , 72, 257-66	138
2045	Challenges in breast cancer clinical trial design in the postgenomic era. 2004 , 16, 536-41	13

2044	Molecular pathology in oncology--the AstraZeneca perspective. 2004 , 5, 1167-73	4
2043	Cancer therapeutics: personal experiences and future perspectives. 2004 , 3, 911-5	7
2042	Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. 2004 , 16 Suppl 4, 36-40	8
2041	Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE). 2004 , 14, 295-300	16
2040	Current World Literature. 2004 , 14, 301-306	
2039	Emerging strategies and applications of pharmacogenomics. 2004 , 1, 444-55	6
2038	Aberrant methylation: common in thymic carcinomas, rare in thymomas. 2005 , 14, 1621	4
2037	Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. 2005 , 65, 3003-10	98
2036	Targets and Approaches for Cancer Drug Discovery. 2005 , 1343-1373	
2035	Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. 2005 , 70, 43-9	21
2034	Use of recombinant factor VIIa for life-threatening bleeding in a patient with severe necrotizing pancreatitis. 2005 , 31, 292-4	1
2033	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. 2005 , 17, 123-9	7
2032	Os nveis sfcos de Cyfra 21-1 sã factores preditivos da sobrevida dos doentes com carcinoma pulmonar de nã pequenas clulas submetidos a gefitinib como terapũtica de terceira linha.. 2005 , 11, 413-415	
2031	Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. 2005 , 128, 3975-84	88
2030	Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung. 2005 , 127, 2292	2
2029	Biologie des cancers bronchiques. 2005 , 2, 1-16	
2028	Lung cancer: genetics of risk and advances in chemoprevention. 2005 , 11, 265-71	24
2027	Granular cell tumor of the pancreas. 2005 , 31, 296-8	8

2026	Dissecting cancer pathways and vulnerabilities with RNAi. 2005 , 70, 435-44	27
2025	Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. 2005 , 70, 419-26	91
2024	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. 2005 , 70, 73-81	34
2023	EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm. 2005 , 12, 47-52	2
2022	Bibliography Current World Literature. 2005 , 11, 345-362	
2021	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. 2005 , 16, 739-42	2
2020	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. 2005 , 17, 118-22	54
2019	Massive biliary pleural effusion induced by pancreatic-thoracic fistula. 2005 , 31, 295-6	
2018	Acute pancreatitis associated with irbesartan therapy. 2005 , 31, 294-5	9
2017	Pancreatic carcinosarcoma with unique triphasic histological pattern. 2005 , 31, 291-2	17
2016	Bibliography. Current world literature. Transplantation. 2005 , 17, 172-9	
2015	Bibliography. Current world literature. Endocrine tumors. 2005 , 17, 61-7	
2014	Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. 2005 , 70, 499-515	24
2013	Lung cancer screening. 2005 , 11, 272-7	7
2012	Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. 2005 , 29, 485-9	38
2011	"Lineage addiction" in human cancer: lessons from integrated genomics. 2005 , 70, 25-34	24
2010	Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. 2005 , 70, 449-59	20
2009	EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. 2005 , 29, 633-9	206

2008	Targeted lung cancer therapy: what have we learned from gefitinib?. 2005 , 2, 1-2	3
2007	Update in oncology. 2005 , 143, 587-92	
2006	Development of Precise Pharmacodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. 2005 , 38, 209-216	1
2005	EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. 2005 , 65, 7568-72	227
2004	Sputum eosinophils and bronchodilator reversibility: COPD or asthma?. 2005 , 127, 2292-3	1
2003	Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. 2005 , 128, 317-21	101
2002	Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 2005 , 28, 481-6	25
2001	New approaches to drug development in pediatric oncology. 2005 , 11, 324-30	16
2000	Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. 2005 , 11, 417-24	57
1999	New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. 2005 , 16, 211-21	26
1998	Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. 2005 , 16, 483-94	41
1997	Association of hepatitis a and acute pancreatitis presenting as acute abdomen. 2005 , 31, 298-9	4
1996	Epidermal growth factor receptor gene is highly conserved in pancreatic cancer cells. 2005 , 31, 299	4
1995	Tailored therapy of colorectal cancer: results, challenges and future directions. 2005 , 11, 175-88	3
1994	In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. 2005 , 106, 227-34	52
1993	Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. 2005 , 106, 3958-61	71
1992	Pharmacogenomics of Cholestatic Liver Disease. 2005 , 407-416	
1991	What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?. 2005 , 2, 290-1	

1990	[Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor]. 2005 , 94, 1831-8	
1989	Activation patterns of epidermal growth factor-receptor signaling in glioblastoma multiforme: in regard to Chakravarti et al. (Int J Radiat Oncol Biol Phys 2005;62:318-327). 2005 , 62, 1253; author reply 1253	
1988	Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core. 2005 , 46, 7381-7384	2
1987	Selective alkylation of a 6,7-dihydroxyquinazoline. 2005 , 46, 7715-7719	9
1986	Targeting ligand cleavage to inhibit the ErbB pathway in cancer. 2005 , 1059, 56-60	3
1985	Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. 2005 , 23, 73-7	32
1984	Evolving molecular-based targeted therapy for cancer: an exciting field. 2005 , 31, 299-305	
1983	Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. 2005 , 19, 385-93	37
1982	Standard treatment in advanced ovarian cancer in 2005: the state of the art. 2005 , 15 Suppl 3, 212-20	53
1981	Diagnostic challenges in pathology. 2005 , 15, 403-405	
1980	CpG Island methylation patterns in various histotypes of endometrial cancer. 2005 , 15, 405-405	
1979	Novel strategies for the management of uterine malignant mixed mullerian tumors. 2005 , 15, 405-405	0
1978	What is the correct management of stage i UPSC?. 2005 , 15, 405-406	2
1977	Advances in the management of advanced and recurrent uterine papillary serous carcinoma. 2005 , 15, 406-406	1
1976	Is lymphadenectomy required for all patients with endometrial cancer?. 2005 , 15, 406-407	2
1975	Laparoscopically assisted surgical staging for endometrial cancer. 2005 , 15, 407-407	12
1974	Updates in chemotherapy in the treatment of advanced and recurrent endometrial cancer. 2005 , 15, 407-408	1
1973	The role of radiation treatment in intermediate risk endometrial cancer-pro. 2005 , 15, 408-409	

1972	Role of radiation treatment in intermediate risk endometrial cancer-con. 2005 , 15, 409-409	1
1971	Future challenges in clinical and translational research for endometrial cancer. 2005 , 15, 398-399	4
1970	Tyrosine kinase inhibitors in endometrial cancer. 2005 , 15, 409-411	15
1969	Novel biologic therapies for the treatment of endometrial cancer. 2005 , 15, 411-411	17
1968	Role of gene expression profiling in distinguishing biologically and clinically distinct subclasses of endometrial carcinoma. 2005 , 15, 403-403	
1967	Early molecular changes in endometrial cancer. 2005 , 15, 399-400	4
1966	Loss of cables is associated with development of endometrial hyperplasia and cancer. 2005 , 15, 400-400	
1965	Endometrial cancer in women with HNPCC. 2005 , 15, 400-401	7
1964	Atypical endometrial hyperplasia: A tough call. 2005 , 15, 401-401	7
1963	Controversies in the management of atypical hyperplasia: Conservative management vs. simple hysterectomy. 2005 , 15, 401-402	
1962	Predictors of poor prognosis in endometrial cancer. 2005 , 15, 402-402	
1961	MSI in endometrial cancer: Prevalence and clinical applications. 2005 , 15, 402-403	2
1960	Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations. 2005 , 31, 384-94	35
1959	Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?. 2005 , 47, 560-4	45
1958	Throwing new light on lung cancer pathogenesis: updates on three recent topics. 2005 , 96, 63-8	19
1957	Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. 2005 , 96, 480-6	38
1956	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. 2005 , 21, 321-39	39
1955	CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. 2005 , 92, 13-4	28

1954	Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. 2005 , 92, 1690-5	26
1953	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). 2005 , 92, 1711-9	122
1952	Role of novel targeted therapies in the clinic. 2005 , 92 Suppl 1, S21-7	11
1951	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. 2005 , 93, 23-8	45
1950	Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. 2005 , 93, 504-9	67
1949	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. 2005 , 93, 1334-40	70
1948	The human cancer genome project--one more misstep in the war on cancer. 2005 , 23, 535-7	52
1947	A small molecule-kinase interaction map for clinical kinase inhibitors. 2005 , 23, 329-36	1569
1946	Response to MoleculeKinase interaction map. 2005 , 23, 1346-1348	0
1945	Plant transgenic science knowledge. 2005 , 23, 1348-9	9
1944	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. 2005 , 37, 48-55	361
1943	Priorities and standards in pharmacogenetic research. 2005 , 37, 671-81	116
1942	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. 2005 , 37, 1315-6	405
1941	Timeline: Chemotherapy and the war on cancer. 2005 , 5, 65-72	1259
1940	ERBB receptors and cancer: the complexity of targeted inhibitors. 2005 , 5, 341-54	2593
1939	Killing time for cancer cells. 2005 , 5, 573-80	77
1938	The concept of synthetic lethality in the context of anticancer therapy. 2005 , 5, 689-98	1061
1937	Biomarkers in cancer staging, prognosis and treatment selection. 2005 , 5, 845-56	1278

1936	Oncogenic PI3K deregulates transcription and translation. 2005 , 5, 921-9	622
1935	Erlotinib hydrochloride. 2005 , 4, 13-4	142
1934	Cancer drug discovery through collaboration. 2005 , 4, 375-80	24
1933	News Analysis. 2005 , 4, 874-875	
1932	Exploiting the PI3K/AKT pathway for cancer drug discovery. 2005 , 4, 988-1004	1618
1931	Carcinogenesis, cancer therapy and chemoprevention. 2005 , 12, 592-602	69
1930	Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. 2005 , 15, 212-7	51
1929	Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. 2005 , 24, 616-26	50
1928	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. 2005 , 24, 829-37	38
1927	Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). 2005 , 24, 1412-22	98
1926	Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. 2005 , 24, 1847-59	67
1925	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. 2005 , 24, 3002-10	101
1924	Identification of molecular apocrine breast tumours by microarray analysis. 2005 , 24, 4660-71	594
1923	The anti-epidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. 2005 , 24, 4433-41	110
1922	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. 2005 , 24, 6646-56	315
1921	AKT crystal structure and AKT-specific inhibitors. 2005 , 24, 7493-501	151
1920	Predominance of high-grade pathway in breast cancer development of Middle East women. 2005 , 18, 891-7	51
1919	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. 2005 , 18, 1027-33	252

1918	Interaction maps for kinase inhibitors. 2005 , 23, 308-9	13
1917	Adding diversity to plant transformation. 2005 , 23, 309-10	15
1916	Targeted therapies for non-small cell lung cancer. 2005 , 59, 1055-62	13
1915	Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. 2005 , 34, 449-59	19
1914	ERBB2 kinase domain mutation in a gastric cancer metastasis. 2005 , 113, 683-7	17
1913	Targeted therapies in breast cancer. 2005 , 11 Suppl 1, S30-5	16
1912	Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. 2005 , 7, 301-11	794
1911	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. 2005 , 7, 387-97	2353
1910	Rational design of shepherdin, a novel anticancer agent. 2005 , 7, 457-68	275
1909	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. 2005 , 7, 575-89	413
1908	Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. 2005 , 8, 227-39	204
1907	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. 2005 , 8, 287-97	348
1906	Combinatorial biomarkers: From early toxicology assays to patient population profiling. 2005 , 10, 781-8	29
1905	2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004. 2005 , 6, 272-275	
1904	2005 Highlights From: 96th Annual Meeting of AACR Anaheim, CA, April 2005 41st Annual Meeting of ASCO Orlando, FL, May 2005. 2005 , 6, 333-337	
1903	Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer. 2005 , 6, 338-9	
1902	Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer. 2005 , 7, 163-5	3
1901	Biologic staging of non-small-cell lung cancer: prospect or proposal?. 2005 , 6, 225-6	

1900	Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. 2005 , 6, 214-6	1
1899	Redefining bronchioloalveolar carcinoma. 2005 , 32, 329-35	20
1898	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
1897	Adjuvant chemotherapy in early-stage non-small cell lung cancer. 2005 , 32, 279-83	10
1896	Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 2005 , 32, S35-41	23
1895	The role of cetuximab in the therapy of previously treated advanced colorectal cancer. 2005 , 32, S55-8	6
1894	An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer. 2005 , 32, S3-8	79
1893	Introduction. 2005 , 32, 1-2	25
1892	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. 2005 , 32, S9-15	69
1891	[Targeted biotherapies in digestive oncology: a new era in therapeutic management?]. 2005 , 29, 495-500	1
1890	The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. 2005 , 129, 1010-7	15
1889	The current clinical value of genomic instability. 2005 , 15, 67-71	11
1888	Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. 2005 , 7, 127-32	29
1887	Recent advances and future perspectives in the management of lung cancer. 2005 , 42, 540-610	1
1886	Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer. 2005 , 94, 1069-77	4
1885	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2005 , 205, 355-63	26
1884	Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. 2005 , 113, 510-1	81
1883	Expression patterns of potential therapeutic targets in prostate cancer. 2005 , 113, 619-28	130

1882	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. 2005 , 116, 36-44	119
1881	Absence of the ERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients. 2005 , 116, 652-3	5
1880	Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. 2005 , 117, 883-8	133
1879	Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia: a Cancer and Leukemia Group B study. 2005 , 103, 651-2	6
1878	Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. 2005 , 103, 1865-73	70
1877	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. 2005 , 103, 2344-8	188
1876	Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. 2005 , 103, 2566-74	67
1875	Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. 2005 , 103, 2435-46	69
1874	EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. 2005 , 33, 228-32	11
1873	Protein-interaction mapping in search of effective drug targets. 2005 , 27, 958-69	14
1872	The molecular biology of esophageal adenocarcinoma. 2005 , 92, 169-90	99
1871	Clinical relevance of ion channels for diagnosis and therapy of cancer. 2005 , 205, 175-84	78
1870	Chronic myeloid leukemia: a model for oncology. 2005 , 84, 487-97	43
1869	Translational studies for target-based drugs. 2005 , 56 Suppl 1, 90-3	11
1868	[Molecular target structures in oncology]. 2005 , 46, 847-8, 850-4, 856-60	2
1867	[Basics of molecular diagnostics and therapy of malignant tumors]. 2005 , 46, 835-6, 838-42, 844-6	0
1866	Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. 2005 , 83, 976-83	25
1865	Genetic analysis of the kinome and phosphatome in cancer. 2005 , 62, 2092-9	47

1864	[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. 2005 , 100, 785-93	2
1863	Blockade of epidermal growth factor receptor (EGFR) activity. 2005 , 53, 179-92	17
1862	Predicting drug response and toxicity based on gene polymorphisms. 2005 , 54, 171-96	86
1861	Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model. 2005 , 55, 103-16	18
1860	Perspektiven der Targeted therapy 2005 , 2, 268-275	
1859	Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). 2005 , 13, 70-2	21
1858	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. 2005 , 446, 483-8	89
1857	Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. 2005 , 131, 649-52	90
1856	Cancer pharmacogenomics: international trends. 2005 , 10, 5-13	20
1855	Intérêt des voies de signalisation EGFR et PDGFR dans le traitement des métastases osseuses du cancer de la prostate hormonorésistant. 2005 , 7, 387-390	
1854	Facteurs pronostiques et prédictifs des cancers bronchiques non à petites cellules. 2005 , 7, 443-446	1
1853	Sensibilité et résistance aux inhibiteurs des récepteurs Erb B. 2005 , 7, 656-659	1
1852	Wirksamkeit von Cetuximab und Irinotecan beim metastasierten kolorektalen Karzinom bei EGF-Rezeptor-negativ. 2005 , 11, 783-784	
1851	Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen. 2005 , 11, 873-888	
1850	Einsatz von Erlotinib: prognostische und prädiktive Faktoren beim nichtkleinzelligen Lungenkarzinom. 2005 , 11, 36-39	
1849	Genomics of lung cancer may change diagnosis, prognosis and therapy. 2005 , 11, 5-10	15
1848	Clinical review of Iressa for the treatment of NSCLC. 2005 , 2, 829-833	
1847	Gefitinib therapy for non-small cell lung cancer. 2005 , 6, 75-81	19

1846	Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. 2005 , 6, 103-14	17
1845	Targeted molecular therapy of malignant gliomas. 2005 , 5, 186-97	44
1844	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2005 , 7, 116-22	4
1843	Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor. 2005 , 7, 123-8	3
1842	Unique issues in the development of "targeted" antineoplastic pharmaceutical agents. 2005 , 7, 235-6	1
1841	Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 2005 , 7, 241-7	21
1840	A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. 2005 , 23, 147-55	31
1839	HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. 2005 , 74, 77-86	60
1838	Molecular biology of medulloblastoma: will it ever make a difference to clinical management?. 2005 , 75, 273-8	26
1837	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. 2005 , 92, 1-9	29
1836	Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors. 2005 , 22, 1069-78	10
1835	EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. 2005 , 22, 1757-61	17
1834	Fibroblast growth factor receptor 2, gain-of-function mutations, and tumorigenesis: investigating a potential link. 2005 , 207, 27-31	21
1833	Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. 2005 , 207, 224-31	126
1832	Biomarkers in molecular medicine: cancer detection and diagnosis. 2005 , Suppl, 9-15	70
1831	A Case of Adenocarcinoma of the Lung Successfully Treated With Alternate Day Administration of Gefitinib. 2005 , 45, 833-837	
1830	CpG ISLAND METHYLATION PATTERNS IN VARIOUS HISTOTYPES OF ENDOMETRIAL CANCER: 0011. 2005 , 15, 405.1-405	
1829	TYROSINE KINASE INHIBITORS IN ENDOMETRIAL CANCER: 0020. 2005 , 15, 409.2-411	

1828	DIAGNOSTIC CHALLENGES IN PATHOLOGY: 0010. 2005 , 15, 403.2-405	
1827	EARLY MOLECULAR CHANGES IN ENDOMETRIAL CANCER: 0001. 2005 , 15, 399-400	4
1826	ENDOMETRIAL CANCER IN WOMEN WITH HNPCC: 0003. 2005 , 15, 400.2-401	
1825	ROLE OF RADIATION TREATMENT IN INTERMEDIATE RISK ENDOMETRIAL CANCER: 0019. 2005 , 15, 409.1-409	
1824	Docetaxel e Nuove Strategie di Trattamento del NSCLC. 2005 , 91, 11-22	
1823	Complexity of cancer as a genetic disease. 2005 ,	
1822	Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. 2005 , 128, 308-16	18
1821	An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. 2005 , 20, 184-188	3
1820	ErbB family of receptors include 4 different receptors, each of which, with the exception of ErbB 2, has a number of ligands. 2005 , 6, 241-2	
1819	Translational Research in Radiation Oncology of Lung Cancer. 2005 , 481-493	
1818	A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. 2005 , 16, 1811-6	109
1817	Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. 2005 , 11, 3668-77	92
1816	A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. 2005 , 2, e312	84
1815	Targeted therapies for esophageal cancer. 2005 , 10, 590-601	114
1814	Receptor tyrosine kinases as targets for anticancer therapeutics. 2005 , 12, 1773-81	13
1813	Practical management of patients with non-small-cell lung cancer treated with gefitinib. 2005 , 23, 165-74	150
1812	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. 2005 , 65, 1459-70	249
1811	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 2005 , 2, e17	1160

1810	Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. 2005 , 16, 1081-6	189
1809	Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. 2005 , 23, 3288-93	60
1808	Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. 2005 , 65, 7525-9	130
1807	Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. 2005 , 11, 5668-70	24
1806	Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. 2005 , 4, 650-8	100
1805	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005 , 2, e73	2628
1804	Expression genomics and drug development: towards predictive pharmacology. 2005 , 3, 303-21	7
1803	Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. 2005 , 35, 233-8	9
1802	Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?. 2005 , 97, 868-9	21
1801	When clinical trials are compromised: a perspective from a patient advocate. 2005 , 2, e358	3
1800	Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. 2005 , 11, 3032-7	113
1799	An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. 2005 , 126, 41-53	105
1798	Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. 2005 , 2, e13	17
1797	EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. 2005 , 2, e75	18
1796	Inhibition of EGFR signaling: all mutations are not created equal. 2005 , 2, e377	35
1795	Acquired gefitinib-resistant mutation of EGFR in a chemo-naive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. 2005 , 2, e269	22
1794	Development of oncology drug response markers using transcription profiling. 2005 , 5, 103-10	6
1793	From traditional biomarkers to transcriptome analysis in drug development. 2005 , 5, 29-38	34

1792	EGFR tyrosine kinase domain mutations in human gliomas. 2005 , 64, 1444-5	62
1791	Targeted therapy: wave of the future. 2005 , 23, 1776-81	46
1790	Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. 2005 , 16, 1817-23	25
1789	Pharmacogenomics steps toward personalized medicine. 2005 , 2, 325-337	60
1788	Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. 2005 , 65, 9176-84	157
1787	Improving cancer therapeutics by molecular profiling. 2005 , 6, 553-68	2
1786	Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases. 2005 , 3, 177-190	
1785	Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?. 2005 , 23, 6813-6	54
1784	Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. 2005 , 65, 6943-9	82
1783	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. 2005 , 2, e313	527
1782	A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?. 2005 , 97, 621-3	22
1781	High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. 2005 , 65, 11478-85	124
1780	Epidermal Growth Factor. 2005 ,	
1779	RESPONSE: Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. 2005 , 97, 462-463	1
1778	Molecular targeting with cancer vaccines. 2005 , 23, 4840-1	5
1777	HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. 2005 , 65, 4253-60	97
1776	Somatic mutations of the protein kinase gene family in human lung cancer. 2005 , 65, 7591-5	392
1775	Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. 2005 , 65, 10524-35	71

1774	Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). 2005 , 65, 1770-7	197
1773	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. 2005 , 11, 5539-48	234
1772	Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. 2005 , 11, 3750-7	269
1771	Translating research into cancer molecular diagnostics and patents. 2005 , 58, 793-4	1
1770	Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. 2005 , 23, 8396-405	110
1769	Development of strategies for the use of anti-growth factor treatments. 2005 , 12 Suppl 1, S173-82	30
1768	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. 2005 , 65, 7276-82	445
1767	A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. 2005 , 11, 3369-76	172
1766	Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. 2005 , 11, 1983-9	114
1765	Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. 2005 , 65, 11631-8	339
1764	Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. 2005 , 4, 938-47	10
1763	Gefitinib versus cetuximab in lung cancer: round one. 2005 , 97, 1168-9	14
1762	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. 2005 , 23, 3227-34	343
1761	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. 2005 , 16, 538-48	39
1760	Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. 2005 , 65, 6401-8	221
1759	Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. 2005 , 11, 8105-8	120
1758	Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. 2005 , 23, 3235-42	183
1757	Targeted therapy with imatinib: hits and misses?. 2005 , 23, 8-10	36

1756 In Reply.. **2005**, 23, 5271-5272

1755 In Reply.. **2005**, 23, 3866-3867

1

1754 In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. **2005**, 11, 7508-15 137

1753 Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. **2005**, 65, 5561-70 285

1752 Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. **2005**, 97, 461-2; author reply 462-3 3

1751 Epidermal growth factor receptor expression in anal canal carcinoma. **2005**, 124, 20-3 54

1750 The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. **2005**, 4, 1349-57 145

1749 Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. **2005**, 4, 641-9 102

1748 Gefitinib in colorectal cancer: if wishes were horses. **2005**, 23, 5446-9 15

1747 Inhibitors of growth factor signalling. **2005**, 12 Suppl 1, S183-7 43

1746 An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. **2005**, 65, 7096-101 231

1745 Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. **2005**, 16, 1906-14 52

1744 Lung cancer in women. **2005**, 23, 3212-8 121

1743 Pharmacogenetics in gastrointestinal tumors. **2005**, 28, 435-40 7

1742 Cytogenetic differences in breast cancer samples between German and Japanese patients. **2005**, 58, 1101-3 7

1741 Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. **2005**, 11, 8872-9 29

1740 Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. **2005**, 280, 19625-34 130

1739 Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?. **2005**, 23, 5856-8 67

1738	An overview of lung cancer genomics and proteomics. 2005 , 32, 169-76	132
1737	Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. 2005 , 23, 1791-3	37
1736	How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. 2005 , 10 Suppl 2, 23-9	20
1735	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. 2005 , 1, 449-60	17
1734	Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. 2005 , 58, 700-4	79
1733	Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. 2005 , 11, 6924-32	277
1732	Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 2005 , 65, 8853-60	75
1731	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. 2005 , 23, 5323-33	286
1730	Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. 2005 , 19, 2078-90	58
1729	Purification and assay of kinase-active EGF receptor from mammalian cells by immunoaffinity chromatography. 2006 , 327, 25-38	4
1728	Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company. 2005 , 127, 385-8	
1727	Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. 2005 , 1, 235-45	12
1726	Factors predicting response to EGFR tyrosine kinase inhibitors. 2005 , 26, 314-22	18
1725	Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. 2005 , 26, 342-52	18
1724	The role of adjuvant chemotherapy for non-small cell lung cancer. 2005 , 26, 298-303	7
1723	Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. 2005 , 237, 342-7	71
1722	Chapter 13 Targeting the Kinome with Computational Chemistry. 2005 , 185-202	2
1721	How will lung cancer be treated in the future?. 2005 , 1, 551-9	0

1720	Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. 2005 , 6, 873-7	39
1719	Epidermal growth factor receptor inhibitors in cancer treatment. 2005 , 1, 221-34	49
1718	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. 2005 , 5, 727-35	2
1717	Clinical advancement of EGFR inhibitors in cancer therapy. 2006 , 327, 189-202	6
1716	Erlotinib hydrochloride. 2005 , 4, S14-S15	18
1715	Pulmonary adenocarcinomas with mutant epidermal growth factor receptors. 2005 , 352, 1724-5	8
1714	Responsiveness to cetuximab without mutations in EGFR. 2005 , 353, 208-9	111
1713	Chasing mutations in the epidermal growth factor in lung cancer. 2005 , 352, 830-2	29
1712	Targeting EGFR in non-small-cell lung cancer. 2005 , 353, 200-2	30
1711	Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. 2005 , 353, 209-10	29
1710	Erlotinib in the treatment of non-small cell lung cancer. 2005 , 5, 767-75	18
1709	Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. 2005 , 6, 603-14	12
1708	Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. 2005 , 1, 319-22	
1707	Hepatocellular carcinoma: molecular pathways and new therapeutic targets. 2005 , 25, 212-25	222
1706	How Cancer Could be Cured by 2015. 2005 , 4, 268-277	35
1705	Genetic profiling of human hepatocellular carcinoma. 2005 , 25, 125-32	46
1704	Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. 2005 , 5, 487-99	26
1703	Chemoprevention of lung cancer: concepts and strategies. 2005 , 5, 549-65	4

1702	Protein microarrays as a discovery tool for studying protein-protein interactions. 2005 , 2, 13-26	20
1701	Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. 2005 , 4, 1381-6	33
1700	Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. 2005 , 23, 5568-77	418
1699	Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. 2005 , 102, 3395-400	283
1698	Gefitinib in non-small cell lung cancer. 2005 , 6, 985-93	41
1697	Pharmacogenomic discovery approaches: will the real genes please stand up?. 2005 , 23, 7342-9	38
1696	Apoptosis-Inducing Anticancer Drugs in Clinical Trials. 2005 , 341-364	
1695	Recent advances in targeted therapy of human myelogenous leukaemia. 2005 , 9, 1147-63	2
1694	Application of Apoptosis to Cancer Treatment. 2005 ,	
1693	ERBB2 in pediatric cancer: innocent until proven guilty. 2005 , 10, 508-17	25
1692	Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. 2005 , 92, 1877-80	16
1691	ZD6474--clinical experience to date. 2005 , 92 Suppl 1, S14-20	55
1690	Targeted antitumour therapy--future perspectives. 2005 , 92 Suppl 1, S28-31	12
1689	Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. 2005 , 93, 915-23	60
1688	Epidemiology informing clinical practice: from bills of mortality to population laboratories. 2005 , 2, 625-34	16
1687	Targeted therapy for epithelial ovarian cancer. 2005 , 9, 501-13	6
1686	Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. 2005 , 93, 355-63	141
1685	EGFR inhibitors: what have we learned from the treatment of lung cancer?. 2005 , 2, 554-61	69

1684	Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. 2005 , 92, 1922-6	60
1683	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005 , 97, 339-46	1919
1682	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. 2005 , 102, 7665-70	827
1681	Epidermal growth factor receptor inhibitors: a moving target?. 2005 , 11, 7203-5	16
1680	Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. 2005 , 11, 4289-94	107
1679	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. 2005 , 23, 2502-12	302
1678	Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. 2005 , 11, 2398-407	80
1677	Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. 2005 , 23, 6976-81	98
1676	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. 2005 , 102, 11011-6	487
1675	Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. 2005 , 13, 319-27	36
1674	Design issues of randomized phase II trials and a proposal for phase II screening trials. 2005 , 23, 7199-206	279
1673	Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. 2005 , 23, 7736-8	7
1672	Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. 2005 , 23, 6172-80	92
1671	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. 2005 , 23, 2544-55	497
1670	Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. 2005 , 11, 7480-9	82
1669	FDA drug approval summary: erlotinib (Tarceva) tablets. 2005 , 10, 461-6	305
1668	Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. 2005 , 10, 104-11	98
1667	The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. 2005 , 280, 31101-8	131

1666	Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. 2005 , 65, 4598-606	98
1665	Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?. 2005 , 23, 921-2; author reply 922	4
1664	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. 2005 , 102, 3788-93	437
1663	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. 2005 , 11, 7841-50	224
1662	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. 2005 , 11, 8686-98	451
1661	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. 2005 , 97, 1185-94	268
1660	10th annual meeting--Association for Molecular Pathology. 2005 , 5, 131-4	
1659	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45	513
1658	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. 2005 , 10, 855-74	8
1657	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. 2005 , 65, 1642-6	569
1656	Genomic profiling of cancer: what next?. 2005 , 23, 7253-6	10
1655	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. 2005 , 97, 880-7	402
1654	Integration/Interaction of Oncologic Growth. 2005 ,	3
1653	Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer. 2005 , 25, 329-35	16
1652	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. 2005 , 23, 5235-46	430
1651	Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 2005 , 23, 3614-21	158
1650	Predicting the future from trials of the past: epidermal growth factor receptor expression and outcome of fractionated radiation therapy trials. 2005 , 23, 5437-9	1
1649	Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. 2005 , 23, 235-7	10

1648	Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. 2005 , 65, 2364-72	24
1647	A survivin gene signature predicts aggressive tumor behavior. 2005 , 65, 3531-4	66
1646	Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. 2005 , 65, 6275-81	190
1645	Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. 2005 , 65, 7137-44	119
1644	HIN-1, an inhibitor of cell growth, invasion, and AKT activation. 2005 , 65, 9659-69	55
1643	Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. 2005 , 11, 6177-85	93
1642	Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. 2005 , 4, 2008-15	62
1641	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. 2005 , 11, 8288-94	193
1640	Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. 2005 , 65, 8151-7	59
1639	In Reply:. 2005 , 23, 922-922	1
1638	The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. 2005 , 10, 467-70	60
1637	Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. 2005 , 65, 8968-74	145
1636	Bexarotene and erlotinib for aerodigestive tract cancer. 2005 , 23, 8757-64	58
1635	Implications of pharmacogenomics for drug development and clinical practice. 2005 , 165, 2331-6	47
1634	Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. 2005 , 11, 8109-13	22
1633	Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 2005 , 11, 2785-808	512
1632	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. 2005 , 23, 9089-96	141
1631	In Reply:. 2005 , 23, 930-931	3

1630	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59	20
1629	The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. 2005 , 2, 341-51	41
1628	Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. 2005 , 65, 9751-61	133
1627	Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. 2005 , 11, 1368-71	124
1626	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. 2005 , 1, 51-61	1
1625	Identifying Biomarkers of Lung Cancer in the Post-Genomic Era. 2005 , 3, 319-331	2
1624	Molecularly targeted therapy for gastrointestinal cancer. 2005 , 5, 171-93	73
1623	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. 2005 , 102, 11858-63	74
1622	Novel targeted therapies in the treatment of gastric and esophageal cancer. 2005 , 16, 1740-8	59
1621	Therapy of breast cancer with molecular targeting agents. 2005 , 16 Suppl 4, iv28-36	35
1620	EGFR gene mutations: a call for global x global views of cancer. 2005 , 97, 326-8	23
1619	Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. 2005 , 3, 151-62	33
1618	Study design issues and early stage non-small cell lung cancer. 2005 , 11, 5030s-5032s	2
1617	Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 2005 , 11, 2300-4	221
1616	DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation. 2005 , 25, 5040-51	40
1615	The ErbB receptors and their ligands in cancer: an overview. 2005 , 6, 243-57	234
1614	Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. 2005 , 27, 317	4
1613	[Basic principles of signal transduction]. 2005 , 28 Suppl 4, 14-7	2

1612	[Clinical development of targeted molecular cancer drugs]. 2005 , 28 Suppl 4, 35-9	3
1611	Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. 2005 , 28, 195-8	7
1610	Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. 2005 , 68, 500-10	17
1609	Inhibitors of epidermal growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. 2005 , 68, 538-47	37
1608	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. 2005 , 28, 623-7	3
1607	[EGF receptor blockade with monoclonal antibodies and so-called "small molecules"]. 2005 , 28 Suppl 4, 18-24	5
1606	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 2005 , 1, 461-6	6
1605	2004: Signaling Breakthroughs of the Year. 2005 , 2005, eg1-eg1	
1604	Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. 2005 , 65, 1778-82	111
1603	Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. 2005 , 11, 6226-32	32
1602	Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. 2005 , 11, 6650-6	132
1601	Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. 2005 , 23, 9265-74	122
1600	Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. 2006 , 125, 860-5	35
1599	Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. 2005 , 4, 435-42	94
1598	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?. 2005 , 4, 1096-7	4
1597	Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. 2005 , 4, 1089-95	10
1596	A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. 2005 , 4, 400-6	30
1595	Biomarkers to predict response to epidermal growth factor receptor inhibitors. 2005 , 4, 1369-72	63

1594	Molecular targeted therapy for lung cancer. 2005 , 366, 1507-8	7
1593	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). 2005 , 366, 1527-37	1802
1592	RNA interference and nonviral targeted gene therapy of experimental brain cancer. 2005 , 2, 139-50	41
1591	Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. 2005 , 11, 2879-82	227
1590	Role of nuclear receptors in lung tumourigenesis. 2005 , 41, 2561-8	29
1589	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. 2005 , 6, 279-86	833
1588	Molecular predictor and promising target: will EGFR now become a star in radiotherapy?. 2005 , 74, 89-91	22
1587	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. 2005 , 76, 162-7	81
1586	Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. 2005 , 24, 3512-24	81
1585	Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. 2005 , 49, 1-12	117
1584	Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. 2005 , 23, 9359-68	286
1583	Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. 2005 , 50, 375-84	136
1582	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. 2005 , 23, 8081-92	551
1581	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. 2005 , 23, 6829-37	641
1580	The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. 2005 , 16, 1334-42	78
1579	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. 2005 , 23, 5007-18	333
1578	Erlotinib in lung cancer - molecular and clinical predictors of outcome. 2005 , 353, 133-44	1594
1577	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005 , 97, 643-55	1367

1576	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. 2005 , 23, 2513-20	839
1575	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. 2005 , 23, 2493-501	681
1574	Race, gender and mutations in the prediction of anti-EGFR activity. 2005 , 1, 201-4	
1573	Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. 2005 , 11, 2106-10	133
1572	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 2005 , 23, 857-65	692
1571	An overview of chemotherapy for mesothelioma. 2005 , 19, 1117-36, vii	26
1570	Looking Forward in Geriatric Anxiety and Depression: Implications of Basic Science for the Future. 2005 , 13, 1027-1040	8
1569	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. 2005 , 7, 396-403	200
1568	Le carcinome bronchiolo-alvéolaire. 2005 , 22, 70-75	3
1567	Clinical applications for targeted therapy in bladder cancer. 2005 , 32, 239-46, vii	6
1566	Lung: Medical Oncology. 2005 , 16, P8-P11	
1565	Targeted therapies for prostate cancer. 2005 , 9, 283-98	10
1564	Overcoming Acquired Resistance to Iressa/Tarceva with Inhibitors of a Different Class. 2005 , 4, 4057-4059	11
1563	The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. 2005 , 9, 769-90	25
1562	Erlotinib in non-small cell lung cancer: a review. 2005 , 6, 995-1002	8
1561	Perspectives on novel therapies for bronchial carcinoma. 2005 , 6, 1157-67	5
1560	Mining the tumor phosphoproteome for cancer markers. 2005 , 11, 3163-9	74
1559	Second-generation kinase inhibitors. 2005 , 9, 975-93	48

1558	Novel therapeutics in adult malignant brain gliomas. 2005 , 14, 643-58	4
1557	LightTyper platform for high-throughput clinical genotyping. 2005 , 5, 457-71	9
1556	Mouse models for human lung cancer. 2005 , 19, 643-64	228
1555	Predictive markers in breast and other cancers: a review. 2005 , 51, 494-503	128
1554	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. 2005 , 23, 5900-9	1250
1553	Genomics and the second golden era of cancer drug development. 2005 , 1, 17-26	43
1552	State of the art in therapy for non-small cell lung cancer. 2005 , 23, 427-42	58
1551	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?. 2005 , 9, 1009-30	45
1550	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. 2005 , 23, 2445-59	613
1549	Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. 2005 , 5, 101-12	11
1548	Spotlight on gefitinib in non-small-cell lung cancer. 2005 , 5, 133-6	4
1547	EGFR pharmacogenomics: the story continues to mutate and evolve. 2005 , 5, 137-9	1
1546	Cancer diagnostics: decision criteria for marker utilization in the clinic. 2005 , 5, 357-64	22
1545	Molecular genetics of acute lymphoblastic leukemia. 2005 , 23, 6306-15	281
1544	Receptor-targeted cancer therapy. 2005 , 24, 271-82	27
1543	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. 2005 , 11, 5878-85	295
1542	Predictors of the response to gefitinib in refractory non-small cell lung cancer. 2005 , 11, 2244-51	161
1541	Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. 2005 , 16, 780-5	69

1540	Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. 2005 , 11, 6414-21	182
1539	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. 2005 , 23, 5892-9	1267
1538	Pharmacogenetics and Drug Development. 2005 , 417-427	
1537	A historical perspective of the EGF receptor and related systems. 2006 , 327, 1-24	41
1536	Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. 2005 , 23, 8253-61	826
1535	Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. 2005 , 23, 3219-26	78
1534	Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. 2005 , 44, 717-22	13
1533	Cyclin D1 in breast cancer pathogenesis. 2005 , 23, 4215-24	317
1532	Regulation of the wild-type and Y1235D mutant Met kinase activation. 2005 , 44, 14110-9	9
1531	Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. 2005 , 65, 1479-88	470
1530	Tyrosine kinases as targets for cancer therapy. 2005 , 353, 172-87	1084
1529	The progress and promise of molecular imaging probes in oncologic drug development. 2005 , 11, 7967-85	194
1528	Advances in Targeted Cancer Therapy. 2005 ,	
1527	Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. 2005 , 36, 486-93	198
1526	Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. 2005 , 36, 1127-34	48
1525	Mutational analysis of gene families in human cancer. 2005 , 15, 5-12	40
1524	Stem cells for lung cancer?. 2005 , 121, 811-3	59
1523	Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. 2005 , 27, 1513-34	82

1522	Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. 2005 , 8, 15-26	111
1521	Resistance to tyrosine kinase inhibitors: calling on extra forces. 2005 , 8, 119-29	33
1520	Resistance to epidermal growth factor receptor-targeted therapy. 2005 , 8, 298-310	66
1519	How to develop a successful cancer drug--molecules to medicines or targets to treatments?. 2005 , 41, 676-82	34
1518	Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. 2005 , 41, 1286-90	44
1517	Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. 2005 , 41, 1383-92	91
1516	Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. 2005 , 224, 117-21	45
1515	Antitumor activity of HER-2 inhibitors. 2005 , 227, 9-23	77
1514	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. 2005 , 230, 33-46	32
1513	Identification of cancer genes by mutational profiling of tumor genomes. 2005 , 579, 1884-90	20
1512	The future of antidepressant pharmacogenetics is arriving. Introduction. 2005 , 29, 996-8	1
1511	Overcoming limitations of natural anticancer drugs by combining with artificial agents. 2005 , 26, 77-81	56
1510	Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?. 2005 , 32, 657-62	13
1509	Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. 2005 , 99, 298-307	13
1508	Molecular Pathology Assays for Breast Cancer. 2005 , 145-168	
1507	Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 2005 , 23, 3279-87	223
1506	Roadmap for developing and validating therapeutically relevant genomic classifiers. 2005 , 23, 7332-41	324
1505	Interstitial lung disease in lung cancer: separating disease progression from treatment effects. 2005 , 28, 103-13	52

1504	Epidermal Growth Factor Receptor as a Target for Chemotherapy. 2005 , 5, S19-S27	47
1503	Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. 2005 , 5 Suppl 2, S62-70	9
1502	Genetic alterations in prostate cancer. 2005 , 3, 220-9	1
1501	Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?. 2005 , 7, 175-9	6
1500	Allele-specific amplification in cancer revealed by SNP array analysis. 2005 , 1, e65	92
1499	Mutated kinases as targets for cancer drugs. 2005 , 2, 139-144	7
1498	Mechanisms of lung cancer. 2005 , 2, 213-223	14
1497	Array-based approaches to cancer genome analysis. 2005 , 2, 171-177	3
1496	Targeted therapy in colorectal cancer: do we know enough?. 2006 , 38, 71-7	5
1495	Biologie des cancers bronchiques. 2005 , 2, 9-31	
1494	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. 2005 , 47, 129-38	118
1493	Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?. 2005 , 47, 325-36	18
1492	Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. 2005 , 48, 141-4	36
1491	Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports. 2005 , 49, 125-8	26
1490	NNK-induced hamster lung adenocarcinomas over-express beta2-adrenergic and EGFR signaling pathways. 2005 , 49, 35-45	56
1489	Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. 2005 , 49, 225-31	44
1488	HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. 2005 , 49, 279-80	3
1487	EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report. 2005 , 49, 413-5	22

1486	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. 2005 , 50, 1-8	105
1485	A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). 2005 , 50, 91-6	38
1484	Consensus on medical treatment of non-small-cell lung cancer—update 2004. 2005 , 50, 129-137	2
1483	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. 2005 , 50, 259-63	8
1482	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. 2005 , 50, 25-33	70
1481	Gefitinib is also active for carcinomatous meningitis in NSCLC. 2005 , 50, 265-9	27
1480	Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. 2005 , 50, 385-91	33
1479	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005 , 352, 786-92	3250
1478	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. 2005 , 353, 2012-24	1211
1477	Novel therapies in lung cancer. 2005 , 19, 343-67, vii	4
1476	Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. 2005 , 7, 426-31	47
1475	[Prostate cancer chemotherapy, myth or reality?]. 2005 , 29, 723-4	
1474	Epidemiology of lung cancer: looking to the future. 2005 , 23, 3175-85	336
1473	Pathogenesis of lung cancer: 100 year report. 2005 , 33, 216-23	104
1472	Erlotinib. 2005 , 4, 247-252	3
1471	Current Advancements in Hard-To-Treat Cancers. 2005 , 4, 105-113	0
1470	Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?. 2005 , 4, 71-84	28
1469	Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. 2005 , 11, 6816-22	125

1468	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. 2005 , 23, 2556-68	525
1467	Intracellular signal transduction pathway proteins as targets for cancer therapy. 2005 , 23, 5386-403	155
1466	Renal-cell carcinoma. 2005 , 353, 2477-90	1231
1465	Erlotinib in previously treated non-small-cell lung cancer. 2005 , 353, 123-32	4590
1464	High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. 2005 , 7, R1186-98	164
1463	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. 2005 , 7, R1028-35	116
1462	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. 2005 , 7, R570-9	94
1461	Variation in tissue-specific gene expression among natural populations. 2005 , 6, R13	121
1460	Anticipating the 1,000 dollar genome. 2006 , 7, 112	131
1459	Mutation of the PIK3CA oncogene in human cancers. 2006 , 94, 455-9	372
1458	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. 2006 , 95, 998-1004	244
1457	Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. 2006 , 5, 223-244	2
1456	Breast Cancer and Molecular Medicine. 2006 ,	2
1455	Lung cancer preneoplasia. 2006 , 1, 331-48	150
1454	Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. 2006 , 8, 46-51	106
1453	Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women. 2006 , 3, 223-35	1
1452	Epidermal growth factor receptor biology in head and neck cancer. 2006 , 24, 2666-72	519
1451	The place of targeted therapies in the management of non-small cell bronchial carcinoma. 2006 , 23, 137-147	2

1450	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. 2007 , 60, 881-4	31
1449	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. 2006 , 3, 269-80	756
1448	Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. 2006 , 95, 1070-5	41
1447	Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. 2006 , 95, 1483-9	148
1446	Pharmacogenomics: challenges and opportunities. 2006 , 145, 749-57	181
1445	Cancer Drug Resistance. 2006 ,	17
1444	Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. 2006 , 10, 67-76	32
1443	Epidermal growth factor receptor as a major anticancer drug target. 2006 , 10, 877-88	6
1442	Should every lung cancer patient be tested for EGFR mutation?. 2006 , 10, 789-91	1
1441	Is EGFR expression important in non-small cell lung cancer?. 2006 , 61, 98-9	33
1440	Cancer therapies targeted to the epidermal growth factor receptor and its family members. 2006 , 16, 147-164	3
1439	Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. 2006 , 24, 310-7	39
1438	Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. 2006 , 11, 274-84	78
1437	Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. 2006 , 66, 1371-5	130
1436	Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. 2006 , 24, 1924-31	543
1435	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. 2006 , 24, 5034-42	623
1434	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. 2006 , 24, 3340-6	449
1433	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. 2006 , 36, 344-50	25

1432	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. 2006 , 52, 225-33	26
1431	Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. 2006 , 24, 1700-4	184
1430	A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. 2006 , 36, 69-75	61
1429	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. 2006 , 24, 64-9	147
1428	Tyrphostins and other tyrosine kinase inhibitors. 2006 , 75, 93-109	180
1427	Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. 2006 , 7, 61-8	9
1426	Where next for gefitinib in patients with lung cancer?. 2006 , 7, 499-507	101
1425	Cancro do pulmão na mulher: Uma entidade diferente?. 2006 , 12, 545-561	
1424	The epidermal growth factor receptor pathway: a model for targeted therapy. 2006 , 12, 5268-72	649
1423	Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. 2006 , 5, 1799-810	168
1422	Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet?. 2006 , 2006, 111-7	31
1421	472 POSTER Development of a 300,000 base pair custom sequencing microarray for biomarker discovery and anticancer drug development. 2006 , 4, 144-145	
1420	473 POSTER p53-dependent repression of CHEK1 contributes to apoptosis in colorectal cancer cells: an in vitro and in vivo study. 2006 , 4, 145	
1419	474 POSTER Inhibition of PDGFR-beta increases sarcoma cell sensitivity to tumor necrosis factor related apoptosis inducing ligand, TRAIL and promotes inhibition of tumor growth in dual therapy using imantinib (Gleevec) and TRAIL. 2006 , 4, 145	
1418	475 POSTER Involvement of the multi-ligand cell surface receptor RAGE in Tumor Necrosis Factor-induced cell death. 2006 , 4, 145-146	
1417	Pharmacogenetics and pharmacogenomics: development, science, and translation. 2006 , 7, 223-45	149
1416	Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbix) results in paradox phosphorylation of tyrosine 1173 in the receptor. 2006 , 580, 4793-800	27
1415	Pharmacogenomics in inflammatory bowel disease. 2006 , 4, 21-8	25

1414	Exploring the human genome in cancer with genomic approaches. 2006 , 17, 1225-33	6
1413	Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. 2006 , 8, 351-6	32
1412	De l'ASCO et du WCLC 2005 à la pratique clinique : thérapies ciblées. 2006 , 62, 30-34	
1411	Recent advances in the treatment of malignant astrocytoma. 2006 , 24, 1253-65	258
1410	Targeting tyrosine kinases in cancer: the second wave. <i>Science</i> , 2006 , 312, 1175-8	33-3 380
1409	Est-il nécessaire de sélectionner les patients pour prescrire des thérapies ciblées dans les cancers bronchiques non à petites cellules de stade IV ? 2006 , 62, 41-44	
1408	La place des thérapies ciblées dans la prise en charge des CBNPC: Mécanismes biologiques de la carcinogenèse bronchique : d'une meilleure compréhension naissent les nouvelles thérapies. 2006 , 23, 123-130	
1407	Novel therapies targeting signaling pathways in lung cancer. 2006 , 16, 379-96, vi	10
1406	Novel targeted therapies for non-small cell lung cancer. 2006 , 16, 353-66	1
1405	Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. 2006 , 8, 504-12	37
1404	A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. 2006 , 8, 335-41	162
1403	The Basal Phenotype of BRCA1-Related Breast Cancer. 2006 , 17, 22-25	
1402	Clinical implications of our advancing knowledge of colorectal cancer genetics: inherited syndromes, prognosis, prevention, screening and therapeutics. 2006 , 86, 787-817	19
1401	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. 2006 , 66, 1441-63	11
1400	Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. 2006 , 6, 59-65	9
1399	Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. 2006 , 6, 208-13	15
1398	Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. 2006 , 7, 385-8	112
1397	Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. 2006 , 8, 22-9	19

1396	Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. 2006 , 7 Suppl 4, S118-25	14
1395	Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. 2006 , 7 Suppl 4, S138-44	61
1394	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. 2006 , 49, 1475-85	72
1393	Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. 2006 , 1, 19	97
1392	Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. 2006 , 24, 2158-63	127
1391	Epidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells. 2006 , 169, 823-30	59
1390	A review of erlotinib and its clinical use. 2006 , 7, 177-93	53
1389	Targeting the ERK signaling pathway in cancer therapy. 2006 , 38, 200-11	318
1388	Pancreatic cancer: a review of recent advances. 2006 , 15, 1395-410	65
1387	Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. 2006 , 407, 612-29	5
1386	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. 2006 , 51, 71-7	49
1385	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. 2006 , 51, 363-8	65
1384	EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. 2006 , 51, 207-15	123
1383	Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. 2006 , 52, 99-103	20
1382	A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. 2006 , 52, 319-25	28
1381	Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. 2006 , 53, 13-21	19
1380	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. 2006 , 53, 117-21	53
1379	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. 2006 , 53, 339-45	15

1378	L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. 2006 , 54, 103-8	29
1377	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. 2006 , 53, 311-22	64
1376	Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. 2006 , 54, 25-33	46
1375	EGFR genotyping in pleural fluid specimens in NSCLC patients. 2006 , 54, 265-6	3
1374	PIK3CA mutation status in Japanese lung cancer patients. 2006 , 54, 209-15	219
1373	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. 2006 , 54, 201-7	31
1372	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. 2006 , 54, 193-9	32
1371	Assessment of molecular events in squamous and non-squamous cell lung carcinoma. 2006 , 54, 293-301	29
1370	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. 2006 , 54, 387-98	88
1369	Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. 2006 , 54, 419-22	50
1368	Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. 2006 , 24, 16-24	1408
1367	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. 2006 , 66, 944-50	446
1366	Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. 2006 , 12, 5064-73	402
1365	A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. 2006 , 22, 561-73	77
1364	Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 24, 2549-56	305
1363	ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas. 2006 , 2, 765-81	32
1362	Gefitinib prevents bleomycin-induced lung fibrosis in mice. 2006 , 174, 550-6	86
1361	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. 2006 , 12, 4283-7	142

1360	Cancer biomarkers--an invitation to the table. <i>Science</i> , 2006 , 312, 1165-8	33:3	171
1359	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. 2006 , 10, 306-15		34
1358	Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. 2006 , 81, 1189-93		68
1357	Molecular and genetic markers in thoracic surgery. 2006 , 82, 2335-6		
1356	Genetic testing for pharmacogenetics and its clinical application in drug therapy. 2006 , 363, 177-86		33
1355	Prognostic biomarkers in non-small-cell lung carcinoma. 2006 , 12, 418-428		7
1354	An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. 2006 , 125, 1137-49		1137
1353	Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. 2006 , 340, 469-75		52
1352	BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. 2006 , 348, 406-12		69
1351	mTOR and cancer: reason for dancing at the crossroads?. 2006 , 16, 78-84		60
1350	Epidermal growth factor receptor (EGFR) signaling in cancer. 2006 , 366, 2-16		1421
1349	Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors. 2006 , 60, 629-32		5
1348	Herceptin: mechanisms of action and resistance. 2006 , 232, 123-38		353
1347	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 2006 , 237, 89-94		39
1346	A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. 2006 , 239, 227-33		30
1345	High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. 2006 , 239, 292-7		22
1344	Predicting the outcome of chemotherapy for lung cancer. 2006 , 6, 323-31		62
1343	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. 2006 , 32, 74-89		137

1342	Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. 2006 , 42, 17-23	133
1341	Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. 2006 , 42, 109-11	142
1340	Targeted kinase inhibitors in lung cancer: from EGFR to patients. 2006 , 42, 124-5	
1339	(CA)n microsatellite polymorphism of ERBB-1 in breast cancer. 2006 , 42, 1698-701	2
1338	Expression of HER1/EGFR protein in human soft tissue sarcomas. 2006 , 32, 466-8	28
1337	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. 2006 , 37, 453-7	20
1336	BRAF and c-kit gene copy number in mutation-positive malignant melanoma. 2006 , 37, 520-7	84
1335	Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. 2006 , 37, 755-63	56
1334	High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East. 2006 , 37, 742-8	14
1333	Interstitial lung disease associated with gefitinib. 2006 , 100, 698-704	30
1332	Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. 2006 , 135, 853-7	25
1331	Clinical experience with anti-EGFR therapy. 2006 , 22, 10-9	11
1330	EGFR-targeted therapy and related skin toxicity. 2006 , 22, 152-62	14
1329	Opiate and acetylcholine-independent analgesic actions of crotoxin isolated from crotalus durissus terrificus venom. 2006 , 48, 175-82	45
1328	Breast cancer. 2006 , 1, 187-210	2
1327	Epidermal growth factor receptor pathway inhibitors. 2006 , 1, 299-310	5
1326	Drugs for Lung Cancer Treatment. 2006 , 60, 123	
1325	Antibody Therapy for Solid Tumors. 2006 , 433-444	

1324	Epidermal growth factor receptor-targeted agents for lung cancer. 2006 , 13, 129-40	16
1323	[The Haplotype Map of the human genome: a revolution in the genetics of complex diseases]. 2006 , 22, 1061-7	4
1322	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. 2006 , 1, 847-855	101
1321	Authors' Reply. 2006 , 3, e207	5
1320	CLINICAL TRIAL DESIGNS FOR CYTOSTATIC AGENTS AND AGENTS DIRECTED AT NOVEL MOLECULAR TARGETS. 2006 , 365-378	
1319	Novel mutations of epidermal growth factor receptor in localized prostate cancer. 2006 , 11, 2518-25	35
1318	FARMACOGENTICA APLICADA AO CANCER. QUIMIOTERAPIA INDIVIDUALIZADA E ESPECIFICIDADE MOLECULAR. 2006 , 39, 577	1
1317	Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. 2006 , 119, 63-68	6
1316	Bronchioloalveolar Carcinoma of the Lung. 2006 , 313-320	
1315	EPIDERMAL GROWTH FACTORS. 2006 , 129-133	3
1314	Cervical Cancer. 2006 ,	
1313	The Trend Toward Personalized Medicine. 2006 ,	
1312	[Drug-induced lung diseases]. 2006 , 127, 425-32	5
1311	Kinase mutations in cancer: chinks in the enemy's armour?. 2006 , 18, 69-76	6
1310	EGF receptor testing for non-small cell lung carcinomas. 2006 , Chapter 10, Unit 10.9	1
1309	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. 2006 , 107, 197-204	25
1308	In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. 2006 , 397, 537-43	13
1307	Creating and enforcing patent rights in the fast moving field of personalized medicine. 2006 , 3, 89-94	0

1306	A useful protocol for analyses of mutations of the epidermal growth factor receptor gene. 2006 , 15, 1503	
1305	Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. 2006 , 331, 139-49	10
1304	EGFR: A Prognostic and/or a Predictive Marker?. 2006 , 1, 395-397	4
1303	BAC Consensus Conference, November 4-6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. 2006 , 1, S2-S7	2
1302	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. 2006 , 1, 520-525	21
1301	Topical Retinoids: Another Piece for the Retinoid-Cigarette-Lung Cancer Puzzle?. 2006 , 1, 732	1
1300	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. 2006 , 1, 406-412	20
1299	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. 2006 , 15, 1205	2
1298	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. 2006 , 1, 31-37	16
1297	Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer. 2006 , 16, 817	
1296	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	24
1295	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. 2006 , 1, 413-416	34
1294	Efficacy of Gefitinib in a Patient with Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. 2006 , 1, 733-734	2
1293	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	2
1292	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. 2006 , 1, 629-634	25
1291	Temozolomide as Prophylaxis for Brain Metastasis in Non-small Cell Lung Cancer. 2006 , 1, 732-733	1
1290	Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. 2006 , 16, 533	1
1289	Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. 2006 , 29, 615-23	6

1288 [Lung cancer in women: a different entity?]. **2006**, 12, 545-61

1287 EGF Receptor Gene Mutations Are Common in Lung Cancers From Never Smokers and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib. **2006**, 2006, 132-134

1286 EGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy. **2006**, 2006, 112-114

1285 EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naïve non-small cell lung cancer. **2006**, 1, 260-7

1284 Angled forceps used for transbronchial biopsy in which standard forceps are difficult to manipulate: a comparative study. **2006**, 129, 725-33

1283 Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. **2006**, 1, 787-795

1282 Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. **2006**, 1, 52-60

1281 Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. **2006**, 1, 367-376

1280 Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. **2006**, 1, 847-855

1279 PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. **2006**, 1, 629-634

1278 Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. **2006**, 1, 413-416

1277 Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity. **2006**, 1, 113-8

1276 Rational Development of Targeted Cancer Therapies Using Biomarkers. **2006**, 37, 482-489

1275 Investigating the molecular basis of drug action and response: chemocentric genomics and proteomics. **2006**, 7, 387-95

1274 Efficacy of Gefitinib in a Patient with Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. **2006**, 1, 733-734

1273 Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer. **2006**, 1, 113-131

1272 Targeting Prenylated RAS Modifying Enzymes in Cancer Cells. **2006**, 1, 285-293

1271 Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia. **2006**, 6, 526-8

1270	Signal Transduction Therapy for Cancer - Whither Now?. 2006 , 1, 1-12	11
1269	Genetic alterations in primary glioblastomas in Japan. 2006 , 65, 12-8	25
1268	Gefitinib Therapy for Pulmonary Adenocarcinoma With EGFR Mutation Diagnosed by Transbronchial Lung Biopsy Using Endobronchial Ultrasonography With Guide Sheath. 2006 , 13, 201-203	1
1267	BAC Consensus Conference, November 4 th , 2004: Epidemiology, Pathogenesis, and Preclinical Models. 2006 , 1, S2-S7	1
1266	Monitoring EGFR-mutant lung cancers by means of the blood. 2006 , 1, 199-200	1
1265	Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. 2006 , 1, 231-9	102
1264	EGFR: A Prognostic and/or a Predictive Marker?. 2006 , 1, 395-397	7
1263	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer. 2006 , 1, 406-412	34
1262	Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRVIII. 2006 , 5, 1361-8	63
1261	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. 2006 , 1, 520-525	29
1260	Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer. 2006 , 1, 635-647	3
1259	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. 2006 , 1, 740-743	4
1258	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. 2006 , 1, 965-971	11
1257	Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?. 2006 , 17, 123-31	31
1256	A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. 2006 , 15, 101-8	28
1255	Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. 2006 , 12, 33-9	21
1254	Erlotinib in-Previously Treated Non-Small-Cell Lung Cancer. 2006 , 2006, 231-233	1
1253	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. 2006 , 1, S13-S19	36

1252	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. 2006 , 1, 31-37	13
1251	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). 2006 , 1, 1-13	38
1250	Matching patients with drugs: triumphs and challenges. 2006 , 3, 335-344	2
1249	Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. 2006 , 17, 783-95	46
1248	Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents. 2006 , 18, 247-52	15
1247	Challenges and opportunities of pharmacogenetics in drug development. 2006 , 3, 195-206	5
1246	Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. 2006 , 17, 95-102	32
1245	Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). 2006 , 18, 307-15	9
1244	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. 2006 , 18, 609-14	3
1243	Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. 2006 , 16, 475-83	90
1242	Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. 2006 , 30, 1309-15	77
1241	Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. 2006 , 17, 401-9	117
1240	Targeted Therapy: Genomic Approaches. 2006 ,	
1239	Translational research in academia and industry. 2006 , 231, 1685-9	6
1238	Effective silencing of EGFR with RNAi demonstrates non-EGFR dependent proliferation of glioma cells. 2006 , 28, 1531	0
1237	Advances in chemotherapy of non-small cell lung cancer. 2006 , 130, 1211-9	139
1236	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. 2006 , 83-132	1
1235	Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. 2006 , 65, 331-46	49

1234	Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. 2006 , 97, 404-9	14
1233	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. 2006 , 11, 287-91	6
1232	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. 2006 , 11, 687-92	27
1231	Worldwide trends in lung cancer pathology. 2006 , 11, 533-8	98
1230	Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. 2006 , 11, 693-8	18
1229	Targeting epidermal growth factor receptor in lung cancer: Perspective from the AsiaPacific region. 2006 , 2, 22-31	1
1228	A semiparametric empirical likelihood method for biased sampling schemes with auxiliary covariates. 2006 , 62, 1149-60	27
1227	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. 2006 , 17, 3-9	10
1226	HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer. 2006 , 260, 484-7	26
1225	The role of pharmacogenetics in cancer therapeutics. 2006 , 62, 35-46	54
1224	New targets and challenges in the molecular therapeutics of cancer. 2006 , 62, 5-14	27
1223	Recent trends in the treatment of advanced lung cancer. 2006 , 97, 448-52	16
1222	High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. 2006 , 97, 642-8	120
1221	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. 2006 , 97, 753-9	64
1220	Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. 2006 , 97, 1366-73	77
1219	PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. 2006 , 97, 1351-8	124
1218	A critical appraisal of prognostic and predictive factors for common lung cancers. 2006 , 48, 779-86	18
1217	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. 2006 , 24, 985-95	108

1216	New approaches to molecular cancer therapeutics. 2006 , 2, 689-700	307
1215	Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. 2006 , 12, 852-5	283
1214	How participants in cancer trials are chosen: ethics and conflicting interests. 2006 , 6, 330-6	12
1213	Comparing antibody and small-molecule therapies for cancer. 2006 , 6, 714-27	531
1212	Lineage dependency and lineage-survival oncogenes in human cancer. 2006 , 6, 593-602	267
1211	Integration of EGFR inhibitors with radiochemotherapy. 2006 , 6, 876-85	233
1210	Impact of genetic diagnostics on drug development strategy. 2006 , 5, 459-62	10
1209	EGF-ERBB signalling: towards the systems level. 2006 , 7, 505-16	1572
1208	COSMIC 2005. 2006 , 94, 318-22	283
1207	Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. 2006 , 94, 631-6	80
1206	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 2006 , 94, 896-903	117
1205	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 2006 , 94, 1136-43	114
1204	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. 2006 , 95, 1390-5	110
1203	Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. 2006 , 95, 1504-13	43
1202	Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. 2006 , 86, 981-6	66
1201	Epithelial growth factor receptor status in primary and recurrent ovarian cancer. 2006 , 19, 607-10	61
1200	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. 2006 , 19, 986-98	16
1199	Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. 2006 , 19, 1213-20	59

1198	Validating cancer drug targets. 2006 , 441, 451-6	131
1197	The second wave in kinase cancer drugs. 2006 , 24, 127-30	51
1196	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. 2006 , 25, 1205-15	111
1195	Comparative and integrative functional genomics of HCC. 2006 , 25, 3801-9	96
1194	Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. 2006 , 25, 5664-72	17
1193	Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making. 2006 , 6, 89-94	16
1192	Use of genomic signatures in therapeutics development in oncology and other diseases. 2006 , 6, 166-73	118
1191	Epidermal growth factor receptor expression and activation in neuroendocrine tumours. 2006 , 18, 355-60	76
1190	Epidermal growth factor receptor directed therapy in head and neck cancer. 2006 , 57, 25-43	44
1189	Is tailored therapy feasible in oncology?. 2006 , 57, 79-101	16
1188	Clinical experience with gefitinib: an update. 2006 , 58, 31-45	46
1187	Proteasome inhibitors in lung cancer. 2006 , 58, 177-89	52
1186	Multitargeted therapy: can promiscuity be praised in an era of political correctness?. 2006 , 59, 150-8	24
1185	Novel targets in gastric and esophageal cancer. 2006 , 59, 128-38	23
1184	Cetuximab in advanced non-small cell lung cancer. 2006 , 59, 139-49	16
1183	Kinase inhibitors in the treatment of renal cell carcinoma. 2006 , 60, 216-26	26
1182	In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. 2006 , 16, 1969-74	64
1181	Prevalence of mutation in the epidermal growth factor receptor gene in Chinese patients with non-small cell lung cancer. 2006 , 18, 635	1

1180	Kinase domain mutation of ERBB family genes is uncommon in acute leukemias. 2006 , 30, 241-2	3
1179	Lack of HLA-E surface expression is due to deficiency of HLA-E transcripts in the malignant hematopoietic cells of leukemic patients. 2006 , 30, 242-5	8
1178	Mutational analysis of the kinase domain of MYLK2 gene in common human cancers. 2006 , 202, 137-40	7
1177	Lung Cancer. 2006 , 552-628	1
1176	FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. 2006 , 25, 147-51	55
1175	Maspin expression and its clinical significance in non-small cell lung cancer. 2006 , 13, 1517-23	27
1174	Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. 2006 , 23, 489-98	41
1173	Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. 2006 , 23, 336-49	24
1172	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. 2006 , 24, 291-7	60
1171	Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment. 2006 , 5, 151-7	6
1170	Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. 2006 , 8, 141-50	106
1169	Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. 2006 , 8, 262-77	89
1168	ErbB receptor negative regulatory mechanisms: implications in cancer. 2006 , 11, 89-99	16
1167	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. 2006 , 95, 211-8	177
1166	Molekular zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. 2006 , 12, 769-779	1
1165	Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. 2006 , 448, 797-804	64
1164	Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. 2006 , 448, 788-96	78
1163	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. 2007 , 133, 93-102	17

1162	Current status and perspective of angiogenesis and antivasular therapeutic strategy: non-small cell lung cancer. 2006 , 11, 73-81	21
1161	Methodological aspects of current problems in target-based anticancer drug development. 2006 , 11, 167-75	17
1160	Biological and clinical implications of EGFR mutations in lung cancer. 2006 , 11, 190-8	169
1159	Resistance to gefitinib. 2006 , 11, 487-91	26
1158	Cancer management can be personalized? [Cancer genomic research in China. 2006 , 5, 156-158	2
1157	A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. 2006 , 57, 533-9	48
1156	Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. 2006 , 58, 460-70	43
1155	Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. 2006 , 58, 577-84	38
1154	Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. 2007 , 59, 183-95	70
1153	Impact of EGFR mutations on treatment of non-small cell lung cancer. 2006 , 58, 5-9	3
1152	Defining clinically relevant molecular subsets of lung cancer. 2006 , 58 Suppl 1, s11-5	16
1151	The impact and role of EGFR gene mutation on non-small cell lung cancer. 2006 , 58, 25-31	7
1150	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. 2006 , 58, 33-37	1
1149	[Current morphological diagnosis of malignant lung tumors]. 2006 , 27, 90-8	3
1148	Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. 2006 , 84, 671-81	109
1147	New antiangiogenetic agents and non-small cell lung cancer. 2006 , 60, 76-86	19
1146	Pankreaskarzinom. 2006 , 1, 27-33	1
1145	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. 2006 , 1, 2-12	2

1144	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. 2006 , 1, 23-33	1
1143	Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. 2006 , 1, 13-22	1
1142	Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring. 2006 , 1, 114-122	
1141	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. 2006 , 1, 151	2
1140	Correlative studies in neuro-oncology trials: should they influence treatment?. 2006 , 8, 54-7	5
1139	Targeted molecular therapy of malignant gliomas. 2006 , 8, 58-70	28
1138	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2006 , 7, 16-22	9
1137	Phosphoinositide 3-kinase: from viral oncoprotein to drug target. 2006 , 344, 131-8	37
1136	Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. 2006 , 101, 18-23	27
1135	Relevant molecular markers and targets. 2006 , 103, S6-S13	15
1134	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. 2006 , 9, 485-95	389
1133	EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. 2006 , 9, 421-3	41
1132	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. 2006 , 10, 39-50	311
1131	Targeting ADAMS and ERBBs in lung cancer. 2006 , 10, 7-11	33
1130	A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. 2006 , 10, 425-35	198
1129	Ligand-independent and EGF receptor-supported transactivation: lessons from beta2-adrenergic receptor signalling. 2006 , 18, 1633-46	52
1128	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 2006 , 1766, 217-29	27
1127	Assessing responses to cancer therapy using molecular imaging. 2006 , 1766, 242-61	45

1126	Pharmacogenetics of cancer chemotherapy. 2006 , 1766, 168-83	13
1125	Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. 2006 , 71, 1422-34	68
1124	Geographic variation in the second-line treatment of non-small cell lung cancer. 2006 , 33, S39-44	6
1123	Optimizing therapy in previously treated non-small cell lung cancer. 2006 , 33, S25-31	7
1122	Use of novel second-line targeted therapies in non-small cell lung cancer. 2006 , 33, S9-16	21
1121	Second-line treatment options in advanced non-small cell lung cancer: current status. 2006 , 33, S3-8	7
1120	Epidermal growth factor receptor targeting in cancer. 2006 , 33, 369-85	560
1119	New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. 2006 , 33, 407-20	209
1118	Variation in the human genome and the inherited basis of common disease. 2006 , 33, S46-9	7
1117	Protein tyrosine kinase-substrate interactions. 2006 , 16, 668-75	52
1116	Radiation combined with EGFR signal inhibitors: head and neck cancer focus. 2006 , 16, 38-44	67
1115	Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. 2006 , 6, 277	46
1114	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. 2006 , 6, 278	42
1113	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. 2006 , 6, 295	223
1112	Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. 2006 , 7, 273-5	44
1111	A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. 2006 , 7, 285-7	15
1110	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. 2006 , 7, 326-31	27
1109	Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. 2006 , 7, 406-11	31

1108	The way forward: new drugs and new therapeutic strategies in lung cancer therapy. 2006 , 7 Suppl 4, S109-10	
1107	Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. 2006 , 8 Suppl 1, S15-22	12
1106	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. 2006 , 7, 289	52
1105	Application of DETECTER, an evolutionary genomic tool to analyze genetic variation, to the cystic fibrosis gene family. 2006 , 7, 44	7
1104	Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. 2006 , 97, 724-34	56
1103	Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. 2006 , 106, 693-702	24
1102	Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. 2006 , 106, 2005-11	258
1101	Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. 2006 , 106, 2200-7	120
1100	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. 2006 , 107, 1034-41	69
1099	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. 2006 , 107, 1207-18	153
1098	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. 2006 , 107, 1866-72	3
1097	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. 2006 , 107, 2858-65	45
1096	Clinical applications of genomics in head and neck cancer. 2006 , 28, 360-8	10
1095	Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. 2006 , 118, 521-2	48
1094	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells. 2006 , 118, 209-14	130
1093	ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. 2006 , 118, 483-9	33
1092	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. 2006 , 118, 1173-80	219
1091	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. 2006 , 118, 963-9	130

1090	Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. 2006 , 118, 1068-9	18
1089	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. 2006 , 118, 257-62	507
1088	Somatic mutations of the ERBB4 kinase domain in human cancers. 2006 , 118, 1426-9	87
1087	Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. 2006 , 118, 1364-9	31
1086	Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer. 2006 , 118, 1545-55	15
1085	Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 2006 , 118, 2498-504	40
1084	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. 2006 , 119, 727-34	16
1083	Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. 2006 , 119, 441-54	26
1082	Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. 2006 , 119, 741-4	106
1081	Frequent EGFR mutations in brain metastases of lung adenocarcinoma. 2006 , 119, 1491-4	152
1080	NNK activates ERK1/2 and CREB/ATF-1 via beta-1-AR and EGFR signaling in human lung adenocarcinoma and small airway epithelial cells. 2006 , 119, 1547-52	78
1079	Accuracy of epidermal growth factor receptor mutation analysis on the basis of small biopsy specimens in patients with nonsmall cell lung cancer. 2006 , 119, 1751-2	8
1078	Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. 2006 , 119, 2527-38	21
1077	Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 2006 , 119, 2586-91	148
1076	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. 2006 , 119, 2353-8	89
1075	ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. 2006 , 119, 2986-7	35
1074	Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. 2007 , 120, 1141-9	15
1073	Anti-angiogenic drugs: from bench to clinical trials. 2006 , 26, 483-530	126

1072	Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. 2006 , 26, 569-94	101
1071	The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. 2006 , 93, 44-6	12
1070	Fluorine-18 labeling of ML04 [p]resently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. 2006 , 49, 533-543	17
1069	Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. 2006 , 5, 360-70	13
1068	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. 2006 , 3, 170-1	16
1067	EGFR targeted therapy: view from biological standpoint. 2006 , 5, 2072-6	27
1066	The basal phenotype of BRCA1-related breast cancer: past, present and future. 2006 , 5, 963-7	43
1065	Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. 2006 , 5, 152-5	25
1064	Elegance, silence and nonsense in the mutations literature for solid tumors. 2006 , 5, 349-59	20
1063	Oncogenic shock: turning an activated kinase against the tumor cell. 2006 , 5, 2878-80	32
1062	Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. 2006 , 84, 42-8	29
1061	C-fos assessment as a marker of anti-epidermal growth factor receptor effect. 2006 , 66, 2385-90	28
1060	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. 2006 , 66, 3197-204	229
1059	Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. 2006 , 66, 11389-98	98
1058	Developing gene expression signatures of pathway deregulation in tumors. 2006 , 5, 2444-9	27
1057	Her2-targeted therapies in non-small cell lung cancer. 2006 , 12, 4377s-4383s	54
1056	Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. 2006 , 66, 9829-36	48
1055	The application of CD antigen proteomics to pharmacogenomics. 2006 , 7, 759-71	10

1054	Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. 2006 , 24, 1428-34	129
1053	Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. 2006 , 24, 2225-6	16
1052	Biological agents versus chemotherapy in the treatment of colorectal cancer. 2006 , 7, 1251-71	2
1051	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. 2006 , 17, 981-5	101
1050	STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. 2006 , 16, 1149-58	131
1049	Point mutations of protein kinases and individualised cancer therapy. 2006 , 7, 2243-61	23
1048	The second annual symposium on the future of lung cancer: a translational focus. 11-12 November 2005, Washington D.C., USA. 2006 , 10, 475-80	
1047	Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. 2006 , 91, 3662-6	53
1046	Expression biomarkers for clinical efficacy and outcome prediction in cancer. 2006 , 7, 105-15	10
1045	Recent Clinical Trials in Non-Small Cell Lung Cancer. 2006 , 2, 81-99	
1044	Der Einfluss genetischer Polymorphismen auf die Wirksamkeit von Medikamenten unter besonderer Berücksichtigung onkologischer Therapien. 2006 , 38, 16-21	
1043	Thin-film technology for direct visual detection of nucleic acid sequences: applications in clinical research. 2006 , 6, 89-99	7
1042	Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma. 2006 , 8, 215-26	73
1041	Update in lung cancer 2005. 2006 , 173, 695-7	6
1040	Tailor-made chemotherapy for non-small cell lung cancer patients. 2006 , 2, 289-99	15
1039	Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. 2006 , 15, 669-90	18
1038	Gefitinib-sensitizing mutations in esophageal carcinoma. 2006 , 354, 2193-4	43
1037	Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. 2006 , 354, 2194-6	20

1036	Pharmacogenomics: from bedside to clinical practice. 2006 , 15 Spec No 1, R89-93	59
1035	An in vivo platform for translational drug development in pancreatic cancer. 2006 , 12, 4652-61	364
1034	Translating genomic biomarkers into clinically useful diagnostics. 2006 , 6, 179-91	46
1033	Dynamics of biological systems: role of systems biology in medical research. 2006 , 6, 891-902	42
1032	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 2006 , 12, 6049-55	173
1031	Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. 2006 , 59, 585-90	42
1030	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. 2006 , 12, 4436s-4440s	29
1029	Protein kinases as drug targets in cancer. 2006 , 6, 623-34	68
1028	Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. 2006 , 24, 2038-43	508
1027	High-throughput mutational analysis of the human cancer genome. 2006 , 7, 597-612	13
1026	Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics. 2006 , 4, 39-46	10
1025	Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. 2006 , 6, 271-94	27
1024	Editorial. 2006 , 2, 1-1	
1023	Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. 2006 , 12, 710-7	104
1022	Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. 2006 , 3, e485	242
1021	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. 2006 , 12, 3381-8	101
1020	Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. 2006 , 5, 1754-63	11
1019	Syphilis: a forgotten priority. 2006 , 3, e204; author reply e207	4

1018	The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours. 2006 , 17 Suppl 10, x263-8	4
1017	Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes. 2006 , 36, 523-6	10
1016	Targeting the EGFR pathway for cancer therapy. 2006 , 13, 3483-92	157
1015	Potential disease targets for drugs that disrupt protein-- protein interactions of Grb2 and Crk family adaptors. 2006 , 12, 529-48	37
1014	Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2006 , 24, 2659-65	131
1013	Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. 2006 , 4, 521-8	119
1012	Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. 2006 , 36, 351-6	51
1011	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. 2006 , 12, 3078-84	85
1010	From integrated genomics to tumor lineage dependency. 2006 , 66, 2506-8	26
1009	Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. 2006 , 66, 2116-28	223
1008	Mouse models of lung cancer. 2006 , 12, 4396s-4402s	35
1007	Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. 2006 , 12, 7222-31	75
1006	Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. 2006 , 11, 655-65	42
1005	Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. 2006 , 24, 5079-90	207
1004	Update on epidermal growth factor receptor mutations in non-small cell lung cancer. 2006 , 12, 7232-41	315
1003	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. 2006 , 5, 1154-65	79
1002	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. 2006 , 12, 7406-13	17
1001	A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. 2006 , 12, 751-8	199

1000	Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. 2006 , 12, 43-8	173
999	Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. 2006 , 12, 7117-25	104
998	Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. 2006 , 126, 608-15	130
997	Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. 2006 , 24, 5253-8	163
996	Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. 2006 , 12, 4421s-4425s	57
995	Exercise induced bronchoconstriction in elite athletes: measuring the fall. 2006 , 61, 94-6	14
994	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. 2007 , 44, 166-72	37
993	EGFR mutation in gefitinib-responsive small-cell lung cancer. 2006 , 17, 1028-9	82
992	Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. 2006 , 24, 4170-6	478
991	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. 2006 , 12, 839-44	597
990	Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. 2006 , 12, 617-25	77
989	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. 2007 , 29, 128-33	11
988	Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. 2006 , 24, 2252-60	122
987	Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. 2006 , 66, 6487-91	121
986	Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. 2006 , 12, 4671-7	56
985	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. 2006 , 5, 209-18	87
984	Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. 2006 , 98, 580-98	167
983	Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. 2006 , 5, 104-13	55

982	Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. 2006 , 12, 1680-5	136
981	A new tumor suppressor gene: invasion, metastasis, and angiogenesis as potential key targets. 2006 , 98, 800-1	6
980	Erlotinib: optimizing therapy with predictors of response?. 2006 , 12, 2961-3	20
979	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. 2006 , 20, 1496-510	363
978	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. 2006 , 12, 4416s-4420s	113
977	Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. 2006 , 61, 140-5	102
976	A blood-based test for epidermal growth factor receptor mutations in lung cancer. 2006 , 12, 3875-7	8
975	Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. 2006 , 66, 7854-8	378
974	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 2006 , 12, 1647-53	356
973	Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction. 2006 , 24, 3319-21	7
972	Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment. 2006 , 57-66	
971	Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. 2006 , 5, 1895-903	12
970	Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. 2006 , 11, 358-73	54
969	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. 2006 , 24, 1679-88	257
968	Drugs Affecting Growth of Tumours. 2006 ,	1
967	HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. 2007 , 60, 768-72	90
966	Targeted therapies in combination with chemotherapy in non-small cell lung cancer. 2006 , 12, 4451s-4457s	16
965	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. 2006 , 12, 4403s-4408s	68

964	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. 2006 , 12, 5764-9	526
963	Lung cancer in never-smokers. 2007 , 60, 337-40	32
962	Cancer risks in LKB1 germline mutation carriers. 2006 , 55, 984-90	81
961	Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. 2006 , 2, 47-51	6
960	Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). 2006 , 5, 1610-27	72
959	Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. 2006 , 3, 50-7; quiz 1 p following 57	102
958	Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. 2006 , 66, 8163-71	315
957	PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. 2006 , 66, 5346-53	58
956	Somatic mutations lead to an oncogenic deletion of met in lung cancer. 2006 , 66, 283-9	364
955	Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. 2006 , 12, 3652-6	54
954	Women and lung cancer. 2006 , 17 Suppl 2, ii79-82	4
953	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. 2006 , 12, 3908-14	479
952	Tobacco Associated Lung Cancer. 2006 , 205-228	
951	RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. 2006 , 24, 4731-7	286
950	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. 2006 , 12, 2538-44	215
949	Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. 2006 , 70, 285-9	59
948	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. 2006 , 66, 5542-8	185
947	Telomerase activation in a model of lung adenocarcinoma. 2006 , 27, 1175-82	20

946	Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response. 2006 , 12, 7252-60	89
945	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. 2006 , 24, 4914-21	450
944	Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. 2006 , 66, 3802-12	51
943	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. 2006 , 66, 10100-11	291
942	Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. 2006 , 12, 57-61	179
941	Genomic approaches to lung cancer. 2006 , 12, 4384s-4391s	40
940	Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. 2006 , 12, 5659-67	180
939	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. 2006 , 12, 6494-501	677
938	Lung cancer genetics and pharmacogenomics. 2006 , 115, 298-302	2
937	Pharmacogenomics: Bench to Bedside. 2006 , 4, 431-441	1
936	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. 2006 , 17 Suppl 2, ii42-45	23
935	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 17, 1120-7	75
934	Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. 2006 , 153, 457-66	30
933	Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. 2006 , 24, 4517-20	210
932	Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. 2006 , 6, 207-27	11
931	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. 2006 , 2, 67-72	
930	The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. 2006 , 12, 4372s-4376s	68
929	Non-small cell lung cancer: second-line and beyond. 2006 , 17 Suppl 10, x97-100	6

928	Targeted therapies in gynecologic cancers. 2006 , 6, 333-63	35
927	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. 2006 , 12, 7242-51	276
926	Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. 2006 , 103, 6901-6	122
925	Systems Biology: a new hope for drug discovery?. 2006 , 1, 653-61	3
924	The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. 2006 , 25, 246-51	11
923	Epidermal growth factor receptor inhibition and non-small cell lung cancer. 2006 , 43, 291-323	14
922	Recent developments in the chemotherapeutic options for nonsmall cell lung cancer. 2006 , 6, 1397-410	
921	Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. 2006 , 281, 40183-92	78
920	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. 2006 , 103, 7817-22	229
919	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. 2006 , 12, 4103-11	209
918	Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. 2006 , 4, 971-81	30
917	Phosphoproteomic analysis of Her2/neu signaling and inhibition. 2006 , 103, 9773-8	175
916	The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. 2006 , 103, 16296-300	178
915	Genotype-specific signal generation based on digestion of 3-way DNA junctions: application to KRAS variation detection. 2006 , 52, 1855-63	12
914	Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. 2006 , 66, 9601-8	174
913	Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. 2006 , 12, 62-9	66
912	Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. 2006 , 3, 256-68	105
911	Les cancers ovariens. 2006 ,	

910	Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. 2006 , 6, 1179-93	30
909	HER2 expression as a potential marker for response to therapy targeted to the EGFR. 2006 , 94, 1144-53	28
908	Malignant melanoma: genetics and therapeutics in the genomic era. 2006 , 20, 2149-82	379
907	Molecular imaging in the development of cancer therapeutics. 2006 , 57, 99-118	96
906	Cetuximab in the treatment of head and neck cancer. 2006 , 6, 1539-52	23
905	Defective assembly of influenza A virus due to a mutation in the polymerase subunit PA. 2006 , 80, 252-61	54
904	Molecular targets in melanoma from angiogenesis to apoptosis. 2006 , 12, 2376s-2383s	40
903	Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. 2006 , 20, 311-3	40
902	Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. 2006 , 66, 6990-7	74
901	Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. 2006 , 103, 2316-21	436
900	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. 2006 , 66, 3162-8	196
899	Significance of EGFR Protein Expression and Gene Amplification in NonSmall Cell Lung Carcinoma. 2006 , 125, 860-865	98
898	Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. 2006 , 11, 602-11	27
897	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. 2006 , 8, 137-44	68
896	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006 , 12, 3915-21	265
895	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. 2006 , 24, 1612-9	181
894	Tumor-associated antigens and biomarkers in cancer and immune therapy. 2007 , 26, 223-47	20
893	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2007 , 12, 325-30	54

892	Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. 2007, 25, 5777-84	177
891	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. 2007, 25, 2164-70	314
890	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. 2007, 7, 821-36	9
889	Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-alpha through the TAK1-p38 signaling pathway. 2007, 282, 12698-706	37
888	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. 2007, 13, 2795-803	222
887	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. 2007, 25, 3936-44	105
886	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. 2007, 6, 2642-51	47
885	Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. 2007, 13, 1540-51	94
884	Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. 2007, 25, 5155-7	35
883	Targeting HER2 in prostate cancer: where to next?. 2007, 25, 241-3	39
882	Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. 2007, 282, 3428-32	88
881	Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. 2007, 6, 308-12	104
880	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. 2007, 6, 471-83	76
879	The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. 2007, 13, 1911-25	59
878	Uncommon tumors and exceptional therapies: paradox or paradigm?. 2007, 6, 1175-9	42
877	Multigene amplification and massively parallel sequencing for cancer mutation discovery. 2007, 104, 9387-92	143
876	The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. 2007, 13, 5763-8	71
875	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. 2007, 67, 2325-30	159

874	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. 2007 , 6, 515-23	22
873	Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioloalveolar carcinoma of the lung. 2007 , 127, 254-62	24
872	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. 2007 , 104, 20932-7	1395
871	Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. 2007 , 71, 508-18	23
870	In Reply. 2007 , 25, 1145-1146	32
869	Systematic analysis of genetic alterations in tumors using Cancer Genome WorkBench (CGWB). 2007 , 17, 1111-7	19
868	CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. 2007 , 4, 603-7	16
867	HER family inhibitors in pancreatic cancer: current status and future directions. 2007 , 11, 337-47	5
866	DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. 2007 , 356, 800-8	407
865	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). 2007 , 96, 1047-51	156
864	'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. 2007 , 97, 1560-6	66
863	Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. 2007 , 13, 2254-60	53
862	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. 2007 , 4, 1669-79; discussion 1680	376
861	Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor. 2007 , 3, 69-77	6
860	Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. 2007 , 37, 725-9	35
859	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. 2007 , 67, 5779-88	102
858	Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. 2007 , 67, 5267-74	130
857	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. 2007 , 8, 554-62	32

856	Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). 2007 , 7, 1755-72	32
855	Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. 2007 , 5, 87-101	2
854	Optimizing Anti-EGFR Strategies in Cancer Treatment. 2007 , 3, 267-275	
853	Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?. 2007 , 4, 1620-2	5
852	Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. 2007 , 298, 70-82	135
851	Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. 2007 , 13, 6518-26	20
850	Ba/F3 cells and their use in kinase drug discovery. 2007 , 19, 55-60	141
849	PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. 2007 , 13, 378-81	108
848	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. 2007 , 4, 1681-89; discussion 1690	261
847	Protein kinase inhibitors: structural insights into selectivity. 2007 , 13, 2751-65	45
846	Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF. 2007 , 293, F895-903	9
845	Genetics of preneoplasia: lessons from lung cancer. 2007 , 7, 3-14	99
844	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. 2007 , 12, 211-20	43
843	Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. 2007 , 9, 271-9	128
842	Targeted therapy of breast cancer. 2007 , 13, 497-517	24
841	Erlotinib in non-small cell lung cancer treatment: current status and future development. 2007 , 12, 840-9	90
840	Detection of epidermal growth factor receptor variations by partially denaturing HPLC. 2007 , 53, 62-70	32
839	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. 2007 , 99, 838-46	258

838	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. 2007 , 13, 5150-5	252
837	Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. 2007 , 6, 2664-74	41
836	Update in lung cancer 2006. 2007 , 175, 868-74	7
835	Future of molecular profiling of human hepatocellular carcinoma. 2007 , 3, 429-39	17
834	Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. 2007 , 131, 1628-34	95
833	Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. 2007 , 132, 597-602	179
832	s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. 2007 , 35, e84	20
831	A translational view of the molecular pathogenesis of lung cancer. 2007 , 2, 327-43	237
830	Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers. 2007 , 2, S128-35	17
829	Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. 2007 , 6, 1336-41	15
828	EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). 2007 , 2, 423-9	68
827	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 2007 , 2, 335-48	3
826	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. 2007 , 8, 1211-20	2
825	Genomics and signaling pathways in hepatocellular carcinoma. 2007 , 27, 55-76	425
824	Drug insight: advances in renal cell carcinoma and the role of targeted therapies. 2007 , 4, 470-9	26
823	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. 2007 , 11, 1287-98	23
822	Molecular biological challenges in the treatment of esophageal adenocarcinoma. 2007 , 1, 275-86	1
821	Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. 2007 , 7, 666-73	18

820	ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. 2007 , 6, 548-54	78
819	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. 2007 , 6, 661-7	72
818	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. 2007 , 1, 203-7	2
817	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. 2007 , 3, 277-83	28
816	Recent advances in targeted therapy for non-small cell lung cancer. 2007 , 11, 245-57	24
815	Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. 2007 , 28, 273-9	33
814	Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. 2007 , 7, 371-93	31
813	Emerging therapies for malignant glioma. 2007 , 7, S29-36	13
812	Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. 2007 , 26, 178-85	17
811	Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma. 2007 , 1, 363-76	2
810	Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. 2007 , 3, 805-17	42
809	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. 2007 , 959-992	2
808	Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. 2007 , 25, 2406-13	192
807	Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. 2007 , 13, 4974-83	76
806	Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. 2007 , 13, 7086-92	58
805	Distinguishing cancer-associated missense mutations from common polymorphisms. 2007 , 67, 465-73	103
804	Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. 2007 , 67, 10831-9	358
803	Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. 2007 , 67, 7807-14	153

802	Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. 2007 , 67, 7695-702	37
801	Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. 2007 , 13, 6788-95	54
800	Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. 2007 , 13, 3413-22	171
799	Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. 2007 , 21, 361-6	7
798	Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. 2007 , 67, 2046-53	133
797	Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. 2007 , 6, 773-81	20
796	Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. 2007 , 13, 434-42	75
795	Biology of interactions: antiepidermal growth factor receptor agents. 2007 , 25, 4057-65	184
794	Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. 2007 , 13, 6087-92	68
793	CETUXIMAB (ERBITUX [®]), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. 2007 , 43-67	
792	p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. 2007 , 67, 1163-9	80
791	Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. 2007 , 13, 3713-23	76
790	Oncogene addiction: setting the stage for molecularly targeted cancer therapy. 2007 , 21, 3214-31	318
789	WWOX expression in different histologic types and subtypes of non-small cell lung cancer. 2007 , 13, 884-91	51
788	Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. 2007 , 67, 11368-76	71
787	Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. 2007 , 13, 52-8	81
786	Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. 2007 , 67, 11867-75	128
785	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. 2007 , 67, 11924-32	589

784	Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 2007 , 128, 100-8	114
783	Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. 2007 , 25, 2528-33	129
782	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. 2007 , 6, 277-85	56
781	Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. 2007 , 67, 2081-8	267
780	An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. 2007 , 2, 387-96	15
779	Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. 2007 , 25, 1145; author reply 1145-6	5
778	Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. 2007 , 13, 5385-90	89
777	Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. 2007 , 67, 1430-5	73
776	Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. 2007 , 37, 907-12	20
775	ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. 2007 , 6, 1579-87	23
774	Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. 2007 , 99, 1257-69	110
773	Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. 2007 , 13, 4-10	37
772	HKI-272 in non small cell lung cancer. 2007 , 13, s4593-6	41
771	The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. 2007 , 13, 6555-60	149
770	Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. 2007 , 67, 7319-26	127
769	Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. 2007 , 13, 4360-4	31
768	Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. 2007 , 6, 244-52	18
767	CUL7 is a novel antiapoptotic oncogene. 2007 , 67, 9616-22	45

- 766 Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. **2007**, 67, 1228-38 67
- 765 Breast Cancer. **2007**,
- 764 Hereditary Breast Cancer. **2007**,
- 763 Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. **2007**, 67, 10417-27 51
- 762 Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. **2007**, 13, s4606-12 42
- 761 Pharmacogenomics. **2007**, 18 Suppl 9, ix24-8 12
- 760 Targeted cancer therapy: promise and reality. **2007**, 97, 295-319 14
- 759 Clairvoyance or reliable prediction of the future?. **2007**, 18, 407-8 2
- 758 Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. **2007**, 6, 2515-24 106
- 757 Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. **2007**, 13, s4628-31 38
- 756 The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. **2007**, 12, 1183-93 51
- 755 The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor. **2007**, 13, 3431; author reply 3431-2 14
- 754 Current status and future of target-based therapeutics. **2007**, 7, 273-84 6
- 753 Pharmacogenomics of Non-Small Cell Lung Cancer. **2007**, 5, 228-234
- 752 Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. **2007**, 3, 276-283
- 751 Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. **2007**, 3, 226-235
- 750 Editorial [The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello]. **2007**, 3, 223-225
- 749 Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside. **2007**, 3, 159-167

748	Non-small cell lung cancer: new hope for a chronic illness. 2007 , 34, 963-70	7
747	Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. 2007 , 25, 4787-92	147
746	EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. 2007 , 67, 4665-70	82
745	Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. 2007 , 67, 6825-43	38
744	Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. 2007 , 13, 2998-3005	34
743	Is there a role for cetuximab in non small cell lung cancer?. 2007 , 13, s4602-5	15
742	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. 2007 , 6, 1079-88	28
741	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. 2007 , 6, 1962-72	109
740	Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. 2007 , 5, 331-9	58
739	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. 2007 , 18, 421-30	36
738	Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). 2007 , 2, 299-305	51
737	From Defining Bioinformatics and Pharmacogenomics to Developing Information-Based Medicine and Pharmacotyping in Health Care. 201-228	3
736	Pharmacogenetics/Pharmacogenomics. 1427-1455	
735	EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. 2007 , 17, 1405	
734	Targets, trials, and travails in pancreas cancer. 2007 , 5, 1042-53	10
733	The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. 2007 , 2, 414-22	35
732	Gender differences: implications for clinical trials and practice. 2007 , 2, S15-8	14
731	Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. 2007 , 2, 1086-90	98

730	Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases. 2007 , 2, 12-21	14
729	Controversy about small peripheral lung adenocarcinomas: how should we manage them?. 2007 , 2, 546-52	13
728	PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. 2007 , 17, 853	5
727	Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. 2007 , 333, 221-5	27
726	[Predictive factors in the response of antiplatelet anti EGFR in gastro-intestinal tumor]. 2007 , 62, 95-8	
725	Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. 2007 , 2, 758-61	31
724	Collagen gel droplet-embedded culture drug-sensitivity test and potential for personalizing cancer treatment. 2007 , 4, 351-356	1
723	EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. 2007 ,	2
722	The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. 2007 , 2, 321-4	4
721	M02-03: Tumor hypoxia and metastasis in non-small cell lung cancers. 2007 , 2, S154-S155	2
720	Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. 2007 , 2, 632-7	57
719	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. 2007 , 2, 430-9	159
718	Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. 2007 , 2 Suppl 2, S68-76	33
717	Overview of genetic diagnosis in cancer. 2007 , Chapter 10, Unit 10.1	
716	E10-04: Management in advanced lung cancer:pain control. 2007 , 2, S247-S249	
715	E13-01: Insights into thymic epithelial tumor: pathology. 2007 , 2, S258-S260	
714	E08-03: Innovative bronchoscopic diagnostic techniques: electromagnetic navigation. 2007 , 2, S239-S241	
713	Increased expression of Gab2, a scaffolding adaptor of the tyrosine kinase signalling, in gastric carcinomas. 2007 , 39, 326-9	32

712	Combination of standard chemotherapy and targeted agents. 2007 , 2, S19-23	2
711	Molecular Biomarkers. 2007 , 41, 573-585	10
710	M02-02: Update of EGFR inhibitors and radiation in the management of non-small cell lung cancer where do we go next?. 2007 , 2, S153-S154	2
709	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. 2007 , 22, 10-23	3
708	Ras pathway activation in malignant mesothelioma. 2007 , 2, 789-95	26
707	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. 2007 , 17, 313-9	49
706	Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. 2007 , 31, 1512-20	29
705	Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. 2007 , 13, 105-13	29
704	Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. 2007 , 15, 242-7	2
703	The role of taxanes and targeted therapies in locally advanced head and neck cancer. 2007 , 19, 195-201	17
702	A Critical Analysis of Nine Premises Underlying Lung Cancer Screening. 2007 , 14, 32-37	1
701	Signal Transduction Therapy: Challenges to Clinical Trial Design. 2007 , 2, 21-30	1
700	Predictive and prognostic markers in neuro-oncology. 2007 , 66, 1074-81	29
699	EGFR-targeting monoclonal antibodies in head and neck cancer. 2007 , 7, 650-65	23
698	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. 2007 , 2, 22-28	33
697	Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. 2007 , 2007, 141-143	
696	Residential Proximity to Naturally Occurring Asbestos and Mesothelioma Risk in California. 2007 , 2007, 108-110	
695	Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. 2007 ,	1

694	Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer. 2007 , 10,	
693	Targeted therapies in bladder cancer--an update. 2007 , 25, 433-8	70
692	Estrogen receptor signaling pathways in human non-small cell lung cancer. 2007 , 72, 135-43	173
691	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 2007 , 10, 81-100	62
690	Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). 2007 , 43, 481-9	121
689	Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). 2007 , 43, 725-35	38
688	Role of tumor markers in patients with solid cancers: A critical review. 2007 , 18, 175-84	131
687	Future Directions for Advanced Thyroid Cancer Therapy. 2016 , 991-999	
686	PET/CT of Lung Cancer. 2016 , 241-266	1
685	Dichotomy of cellular inhibition by small-molecule inhibitors revealed by single-cell analysis.	1
684	Lung Cancer. 2016 , 419-432	
683	Lung Cancer Among Asian Americans. 2016 , 107-136	
682	The Era of Personalized Cancer Treatments. 2016 , 62, 2-6	
681	Current status and prospects of targeted therapies non-small cell lung cancer. 2016 , 10, 15-18	
680	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. 2015 , 4, 160	2
679	- Gene Body Methylation and Transcriptional Regulation: Statistical Modelling and More. 2016 , 225-243	
678	Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables. 2016 , 37, 189-95	3
677	Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. 2016 , 7, 514-524	1

- 676 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726
- 675 Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. **2016**, 16, 280-285 1
- 674 Dissecting cancer resistance to therapies with cell-type-specific dynamic logic models. 1
- 673 Molecular Pathology of Lung Tumors. **2017**, 611-638
- 672 Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics. 1
- 671 Synthetic Peptide Libraries. **2017**, 143-159
- 670 The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis. **2017**, 07, 117-129
- 669 The execution of molecular genetic tests using DNA of tumor cells obtained from cytologic preparations. **2017**, 6, 23 2
- 668 Methods in Molecular Diagnosis. **2017**, 63-77
- 667 Companion Diagnostics. **2017**, 117-136
- 666 Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. **2017**, 273-289
- 665 Locally Advanced Non-small Cell Lung Cancer and Targeted Therapy. **2017**, 155-165
- 664 EGFR Mutant. **2017**, 167-189
- 663 Accurate Nodal Staging and Biomarker Testing with Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. **2017**, 79-96
- 662 Identification and Validation of Driver Kinases from Next-Generation Sequencing Data. **2017**, 1636, 179-195
- 661 Collective effects of common SNPs and improved risk prediction in lung cancer. 6
- 660 Classifying cancer genome aberrations by their mutually exclusive effects on transcription.
- 659 Predicting ligand-dependent tumors from multi-dimensional signaling features.

658 2. State of the Art of EGFR-TKI and Future Perspectives. **2017**, 106, 1096-1100

657 Final amendment: Ambiguous specification of EGFR mutations compounded by nil or negligible fragmented gene counts and erroneous application of the Kappa statistic reiterates doubts on the veracity of the TEP-study.

656 I. Diagnosis of the Molecular Aberrations in Non-small Cell Cancer. **2017**, 106, 1082-1088

655 Analysis of Copy Number Loss of the ErbB4 Receptor Tyrosine Kinase in Glioblastoma.

654 Early Diagnosis with 11-Gene Panel Screening for Non Small Cell Lung Cancer. **2017**, 8,

653 Synergistic Antitumor Effect of Genitinib (Iressa´ □) with Flavonoids from the Scutellaria baicalensis Root on the Non-Small Cell Lung Cells. **2017**, 10, 62-69 ○

652 Whole-exome sequencing of plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and enables the discovery of mutatedKDR/VEGFR2 receptors as modulators of anti-angiogenic therapies.

651 Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS). **2018**, 93-108

650 Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. **2017**, 8, 100754-100763 3

649 Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.

648 AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES. **2017**, 46-55

647 Serum proteins can successfully predict self-reported ethnicity: Implications for precision-medicine.

646 Hyperactivation of extracellular signal-regulated kinase (ERK) by RAS-mediated signaling or inhibition of dual specificity phosphatase 6 (DUSP6) is associated with toxicity in lung adenocarcinoma cells with mutations in KRAS or EGFR.

645 The cancer-mutation network and the number and specificity of driver mutations.

644 Serous Effusion Cytology. **2018**, 235-257

643 Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without -mutated Lung Adenocarcinoma. **2018**, 32, 203-209

642 Partial Correlations. **2018**, 387-392

641 Genome-wide identification of CDC34 that stabilizes EGFR and promotes lung carcinogenesis.

640 Relative Chemo-, Hormonal, and Immunosensitivity. **2018**, 29-40

639 ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in early stage Gallbladder Cancer.

638 Inhibition of mitochondrial ferredoxin 1 (FDX1) prevents adaptation to proteotoxic stress.

637 Computational Disease Subtyping based on Joint Analysis of Clinical and Genomic Data.

636 Detecting Mutations in Patients with Non-small Cell Lung Cancer. **2018**, 21, 13-17

1

635 Diagnosis and Treatment of Non-Squamous Lung Cancer Based on Molecular Tumor Testing. **2018**, 93, 266-270

634 LOTUS: a Single- and Multitask Machine Learning Algorithm for the Prediction of Cancer Driver Genes.

633 The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with T790M mutation to anti-EGFR drugs in non-small cell lung cancer. **2018**, 20, 10-18

632 Kİ Hİcreli Dİ AkciĐer Kanseri Hastalarında Onkogen Mutasyonların AraĐılması

631 Association of CT-based imaging features and genomic data in non-small cell lung cancer. **2018**,

630 Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions. 001-005

629 Molecular Targeted Therapy of Lung Cancer. **2018**, 14, 177-179

628 Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.

627 The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790M mutation and their significance in clinical practice. **2018**, 5, 17-24

626 Reporting Clinical Genomic Assay Results and the Role of the Pathologist. **2019**, 253-266

625 Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran. **2019**, 14, 1-7

624 Unmet Needs and Future Outlook of Mesothelioma Management. **2019**, 331-340

623 Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines.. **2019**, 2, 539-549

- 622 Clinical Strategies for Developing Next-Generation Cancer Precision Medicines. **2019**, 105-117
- 621 Recent Advances in the au NP Treatment Strategies of Lung Cancers. **2019**, 701-729
- 620 Somatic mutations in miRNA genes in lung cancer [potential functional consequences of non-coding sequence variants. 0
- 619 Clinically-relevant cell type cross-talk identified from a human lung tumor microenvironment interactome. 1
- 618 Multiple-line Chemotherapy and Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung Cancer. **2019**, 22, 27-34 1
- 617 Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.. **2019**, 8, 736-751
- 616 Discovering novel long non-coding RNA predictors of anticancer drug sensitivity beyond protein-coding genes.
- 615 Patterns of brain metastasis in anaplastic lymphoma kinase - rearranged and epidermal growth factor receptor-mutated lung cancer patients in magnetic resonance imaging. **2019**, 8, 189-190 1
- 614 Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. **2019**, 20, 2415-2420 1
- 613 Lung Carcinoma. **2020**, 83-101
- 612 In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectability.
- 611 Molecular targeted therapies in non-small cell lung cancer: where we are. **2019**, 8, S222-S223 1
- 610 Effect of icotinib on advanced lung adenocarcinoma patients with sensitive mutation detected in ctDNA by ddPCR.. **2019**, 8, 2858-2863 1
- 609 Lung Cancer. **2020**, 13-30
- 608 Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
- 607 Systemic Therapy of Brain Metastases: Lung Cancer. **2020**, 207-217
- 606 Genetik menschlicher Erkrankungen. **2020**, 725-812
- 605 Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study. 1-1 0

- 604 The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. **2020**, 5, 048-053 1
- 603 Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling.
- 602 Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma. **2020**, 164, 127-132
- 601 Tertiary Lymphoid Structure and CD8 T Cell Exclusion in Minimally Invasive Adenocarcinoma. 1
- 600 Current Status of Translational Research in Lung Cancer and Perspectives and Challenges of Academic Translational Research in Japan. **2020**, 60, 305-313
- 599 Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma. **2020**, 12, 16514-16538 3
- 598 VA National Precision Oncology Program. **2020**, 37, S22-S27
- 597 Quantification of [F]afatinib using PET/CT in NSCLC patients: a feasibility study. **2020**, 10, 97 1
- 596 Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations.
- 595 Technical aspects of the use of cytopathological specimens for diagnosis and predictive testing in malignant epithelial neoplasms of the lung. **2021**, 0
- 594 Untargeted Lipidomics of Non-Small Cell Lung Carcinoma Demonstrates Differentially Abundant Lipid Classes in Cancer vs. Non-Cancer Tissue. **2021**, 11, 2
- 593 HER-2 positivity is a high risk of recurrence of stage I gastric cancer. **2021**, 36, 1327-1337 1
- 592 Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. **2021**, 6, 374 1
- 591 Identification of Stage IIIc/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model. **2021**, 11, 721318 1
- 590 Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective Study.
- 589 Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. **2020**, 66, 403-409
- 588 A CRISPR Competition Assay to Identify Cancer Genetic Dependencies. **2020**, 10, e3682 1
- 587 Rapid and Sensitive Detection of UGT1A1 Polymorphisms Associated with Irinotecan Toxicity by a Novel DNA Microarray. **2020**, 69, 161-168

- 586 Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?. **2020**, 9, 2518-2520
- 585 An Overview of Promising Biomarkers in Cancer Screening and Detection. **2020**, 20, 831-852 1
- 584 Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy. **2020**, 194-198
- 583 Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. **2022**, 207-230
- 582 Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. **2020**,
- 581 Therapy Response Imaging in Thoracic Malignancy. **2020**, 79-97
- 580 Identification of Stage IIIc/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.
- 579 Lessons for Precision Medicine from Lung Cancer. **2020**, 201-223
- 578 Tumour Content Ratio Matters for Detecting Epidermal Growth Factor Receptor Mutation by Cobas Test in Small Biopsies; a Retrospective Study.
- 577 The Pharmacogenomics "Side-effect" of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis. **2019**, 19, 2060-2071 0
- 576 Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. **2020**, 55-82
- 575 Interindividuelle Unterschiede. **2020**, 61-69
- 574 CHAPTER 8:Chemical Probes for Kinases. **2020**, 182-213
- 573 Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. **2020**, 66, 392-402
- 572 A novel loop-mediated isothermal amplification method for efficient and robust detection of EGFR mutations. **2020**, 56, 743-749 3
- 571 Cancfoгенсе et maladie cançeuse. **2020**, 31-35.e1
- 570 The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of Cancer.
- 569 Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters. **2020**, 12, e7316

568	Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer from different ethnic groups. 2020 , 19, 3513-3520	1
567	In silico Identification of Peptide as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Treatment. 2020 , 23, 567-574	1
566	Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy. 2021 , 11, 761986	0
565	A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer.. 2022 , 13, 312-323	3
564	Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. 2021 , 4, e2133205	8
563	Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas. 2020 , 20, 2987-2996	1
562	EGF signaling in bowel carcinoma cells utilizes higher order architectures of EGFR and HER2.	
561	Multi-omics integrative analysis and survival risk model construction of non-small cell lung cancer based on The Cancer Genome Atlas datasets. 2020 , 20, 58	1
560	Fundamental Aspects of the Cell Cycle and Signal Transduction. 2006 , 207-213	
559	Targeting Oncogenes Which Regulate Apoptosis. 2005 , 117-144	
558	Aspects morphologiques et moléculaires des lésions pré-invasives broncho-pulmonaires : impact sur leur évolutivité 2005 , 89-110	
557	Les thérapies ciblées ou le traitement des mécanismes moléculaires de la progression tumorale. 2006 , 515-527	
556	Die Zukunft der Genetik Zwischen Gentechnik und Genomforschung. 1995 , 763-784	
555	Pathologic and Molecular Techniques Used in the Diagnosis and Treatment Planning of Sarcomas. 2006 , 13-34	
554	Molecular Staging of Non-Small-Cell Lung Cancer. 2006 , 159-176	2
553	Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer. 2006 , 261-270	
552	Chemoprevention of Lung Cancer. 2006 , 609-626	
551	Molecular Biology of Lung Cancer. 2006 , 67-80	

550 Signal transduction inhibitors. **2006**, 185-199

549 Dawn of a new era in molecular cancer therapeutics. **2005**, 63, 1-17

1

548 Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. **2008**, 291-306

547 Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. **2008**, 307-316

1

546 Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. **2008**, 371-387

545 The current and future roles of genomics. 79-94

544 Molecular pathology. 95-118

1

543 Angiogenesis Inhibitors for the Treatment of Lung Cancer. **2008**, 409-426

0

542 The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. **2007**, 335-357

541 Tyrosine Kinase Inhibitors. **2007**, 477-508

540 Expression Profiling of Prostate Cancer Progression. **2007**, 247-267

539 Somatic Alterations in Prostate Cancer Progression. **2007**, 269-283

538 Untargeted Use of Targeted Therapy. **2008**, 227-240

537 Patient Selection for Rational Development of Novel Anticancer Agents. **2008**, 641-648

536 How to Define Treatment Success or Failure if Tumors Do Not Shrink. **2008**, 657-674

535 Molecular Targeting of Colorectal Cancer. **2008**, 133-163

534 Combining Targeted Therapies. **2008**, 361-381

533 Targeted lung cancer therapy: what have we learned from gefitinib?. **2005**, 2, 1-2

532	Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer. 2006 , 643-670	
531	RNA interference and nonviral targeted gene therapy of experimental brain cancer. 2005 , 2, 139-150	
530	Signal Transduction of a Novel WBP2 Oncogene. 2020 , 14, 3-13	
529	Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer. 2015 , 7, 875-80	10
528	A time to test, a time to treat. 2012 , 4, 223-5	1
527	Molecular determinants of lung cancer metastasis to the central nervous system. 2013 , 2, 273-83	12
526	[A comparison of direct sequencing and ARMS assay performance in EGFR mutation analysis of non-small cell lung cancer patients]. 2014 , 17, 606-11	3
525	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. 2015 , 3, 81	9
524	TRAIL apoptotic pathway-targeted therapies for NSCLC. 2012 , 1, 155-7	2
523	Therapeutic modalities for Pancoast tumors. 2014 , 6 Suppl 1, S180-93	34
522	Renal cell carcinoma and the use of sorafenib. 2006 , 2, 87-98	11
521	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. 2007 , 118, 253-61	4
520	The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer. 2008 , 19, 217-24	10
519	HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. 2007 , 1, 221-7	16
518	Cancer as a system failure. 2007 , 5, 10-8	
517	Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. 2008 , 58, 276-81	7
516	Review of erlotinib in the treatment of advanced non-small cell lung cancer. 2007 , 1, 335-46	22
515	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. 2007 , 1, 185-94	4

514	Pharmacogenetics: implementing personalized medicine. 2009 , 6, 17-24	28
513	The role of pharmacogenetics and pharmacogenomics in improving translational medicine. 2009 , 6, 13-6	2
512	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. 2010 , 36, 19-27	4
511	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. 2009 , 15, 213-20	8
510	Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. 2008 , 2, 17-25	3
509	Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. 2008 , 4, 1-13	6
508	Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. 2011 , 4, 403-9	3
507	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
506	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. 2011 , 36, 263-79	14
505	N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. 2011 , 1, 823-33	19
504	Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. 2010 , 2, 48-51	184
503	The role of gene expression profiling in early-stage non-small cell lung cancer. 2010 , 2, 89-99	27
502	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. 2010 , 2, 189-91	1
501	Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer. 2012 , 4, 82-5	
500	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. 2010 , 10, 1-48	23
499	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. 2012 , 4, 226-8	2
498	Receptor tyrosine kinases: role in cancer progression. 2006 , 13, 191-3	32
497	A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. 2012 , 5, 112-8	5

496	The 5 stages of biotechnology management. 2005 , 2, 45-50	
495	Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. 2013 , 5, 200-11	30
494	Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. 2010 , 10, 44-51	53
493	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. 2013 , 5, 481-96	13
492	Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases. 2014 , 7, 1266-74	20
491	Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer. 2014 , 6, 503-6	1
490	Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer. 2014 , 4, 293-302	1
489	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. 2014 , 17, 101-14	35
488	EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. 2014 , 4, 411-35	96
487	Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. 2011 , 4, 1-35	5
486	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. 2014 , 6, S568-80	8
485	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. 2014 , 12, 429-39	167
484	Fatal interstitial lung disease associated with icotinib. 2014 , 6, E267-71	4
483	Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing. 2014 , 7, 8813-22	23
482	Expanding options for EGFR targeting in lung cancer. 2012 , 1, 287-8	2
481	Treating acquired resistance to EGFR-tyrosine kinase inhibitors: still a work in progress. 2012 , 1, 149-51	1
480	Advances on EGFR mutation for lung cancer. 2012 , 1, 5-13	38
479	Apoptotic agents. 2013 , 2, 238-43	3

478	Influence of chemotherapy on EGFR mutation status. 2013 , 2, 442-4	7
477	10(th) Congress on Lung Cancer-updates on clinical trials: goal. 2014 , 3, 66-9	1
476	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. 2013 , 2, 411-4	1
475	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. 2015 , 7, 224-6	1
474	Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a decade of progress and hopeful future. 2015 , 7, 217-9	
473	Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance of human hepatic cancer HepG2/G cell line. 2015 , 8, 3063-71	15
472	Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients. 2015 , 27, 294-300	4
471	Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. 2015 , 5, 1692-705	25
470	Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. 2015 , 5, 2229-40	5
469	Somatic mutation in synchronous primary adenocarcinomas of the left lung: a case report. 2015 , 8, 8579-84	
468	EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. 2015 , 8, 8603-6	14
467	Screening feature genes of lung carcinoma with DNA microarray analysis. 2015 , 8, 12161-71	9
466	Expression pattern of FGFR2, Grb2 and Plc β acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. 2015 , 5, 3135-48	9
465	Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition. 2015 , 7, 2026-35	22
464	Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer. 2015 , 8, 22300-9	5
463	Getting familiar with the forthcoming eighth edition of TNM classification of lung cancer: from the T to N and M descriptors. 2016 , 4, 67	2
462	A perspective on anti-EGFR therapies targeting triple-negative breast cancer. 2016 , 6, 1609-23	115
461	LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer. 2016 , 8, 5025-5034	64

460	Drug resistance in lung cancer. 2010 , 1, 23-36	54
459	Role of epidermal growth factor receptor in lung cancer and targeted therapies. 2017 , 7, 187-202	39
458	The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. 2017 , 7, 962-972	29
457	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. 2017 , 18, 107-114	9
456	Pancreatic adenocarcinoma protein-protein interaction network analysis. 2017 , 10, S85-S92	12
455	Evaluation of involved proteins in colon adenocarcinoma: an interactome analysis. 2017 , 10, S129-S138	4
454	[Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System ?Metastases from Non-small Cell Lung Cancer]. 2016 , 19, 496-500	
453	[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors]. 2017 , 20, 720-726	1
452	[Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer ?in Different Genotypes]. 2017 , 20, 741-750	1
451	[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. 2017 , 20, 617-622	3
450	[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy]. 2011 , 14, 699-703	
449	[Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer]. 2016 , 19, 766-772	
448	[Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer]. 2011 , 14, 245-50	2
447	[The detection methods of EGFR mutations in non-small cell lung cancer]. 2011 , 14, 297-302	0
446	[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma]. 2011 , 14, 127-31	3
445	[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. 2015 , 18, 110-6	
444	[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib]. 2012 , 15, 513-20	1
443	[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. 2012 , 15, 127-38	0

- 442 [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines]. **2011**, 14, 478-83 2
- 441 [Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report]. **2015**, 18, 592-8
- 440 [Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases]. **2015**, 18, 554-8 1
- 439 [Progress in immunotherapy for non-small cell lung cancer]. **2014**, 17, 34-41 0
- 438 [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor ?Receptor Mutations in Non-small Cell Lung Cancer]. **2015**, 18, 493-9 4
- 437 [Gender-associated differences of lung cancer and mechanism]. **2011**, 14, 625-30
- 436 [Immunohistochemical detections of EGFR status in NSCLC]. **2015**, 18, 212-8
- 435 [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib]. **2015**, 18, 193-8
- 434 [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China]. **2012**, 15, 332-9 3
- 433 [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma]. **2015**, 18, 686-90 1
- 432 [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis]. **2010**, 13, 882-91 10
- 431 [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography]. **2010**, 13, 850-5 1
- 430 [EGFR mutation status in Uighur lung adenocarcinoma patients]. **2013**, 16, 78-81
- 429 [Treatment of advanced NSCLC with unknown EGFR gene status?--TKI or chemotherapy?]. **2014**, 17, 709-14
- 428 [Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer]. **2013**, 16, 33-7
- 427 [Treatment progress for EGFR wild-type advanced non-small cell lung cancer]. **2014**, 17, 575-80
- 426 [Effects of monoclonal antibody cetuximab on proliferation of non-small cell lung cancer cell lines]. **2010**, 13, 769-72 1
- 425 [Clinical significance of ROS1 rearrangements in non-small cell lung cancer]. **2013**, 16, 663-70

- 424 [Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance]. **2013**, 16, 510-3
- 423 [Advance of Treatment for Superior Sulcus Tumor of the Lung]. **2018**, 21, 493-497
- 422 [Personalized targeted therapy for lung cancer]. **2013**, 16, C21-34
- 421 [Anatomy, biology and concepts, pertaining to lung cancer stage classification]. **2010**, 13, 1-8 1
- 420 Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. **2018**, 8, 2575-2589
- 419 Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells. **2018**, 10, 4183-4192 4
- 418 Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients. **2019**, 9, 619-627 6
- 417 Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations. **2019**, 9, 1708-1721 2
- 416 [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis]. **2019**, 39, 641-649
- 415 [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer?with Uncommon EGFR Mutations]. **2019**, 22, 590-599 0
- 414 Identification of EGFR mutations in cytological specimens of non-small cell lung carcinoma from a single institute. **2018**, 11, 929-935 1
- 413 Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion. **2018**, 11, 2811-2815
- 412 Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer. **2018**, 11, 4644-4649
- 411 Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma. **2020**, 13, 525-535 1
- 410 Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement. **2020**, 11219,
- 409 Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. **2020**, 12, 5505-5516
- 408 Evaluation of quantitative modeling methods in whole-body, dynamic [C]-erlotinib PET. **2021**, 11, 143-153 0
- 407 Immunotherapy in non-small cell lung cancer: Update and new insights. **2021**, 7, 1-21 4

406	Identification of the Key Genes of Autism Spectrum Disorder Through Protein-Protein Interaction Network. 2019 , 8, e1367	
405	Sensitive detection of T790M mutations in lung cancer biopsies using a PCR-based lateral flow assay. 2022 , 637, 114476	
404	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. 2021 , 1877, 188645	4
403	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. 2021 ,	26
402	Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteiny Amide Inhibitors. 2021 , 13,	1
401	Pathology and Cancer Genomic Medicine. 2021 , 61, 887-892	
400	Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer. 2021 ,	
399	No-boundary thinking: a viable solution to ethical data-driven AI in precision medicine. 2021 , 1-9	0
398	Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands. 2021 , 22,	4
397	Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1.. 2021 , 24, 103528	0
396	Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). 2021 ,	8
395	Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features. 2021 ,	0
394	MCP-1 targeting: Shutting off an engine for tumor development. 2022 , 23, 26	0
393	Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. 2021 , 13,	2
392	Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing-a single-center experience.. 2021 , 10, 4221-4234	0
391	EasyCatch, a convenient, sensitive and specific CRISPR detection system for cancer gene mutations. 2021 , 20, 157	0
390	Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. 2021 , 12, 7014	0
389	Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik.	

- 388 A case of small-cell lung cancer harboring an epidermal growth factor receptor mutation that responded to epidermal growth factor receptor tyrosine kinase inhibitor treatment. **2020**, 7, 78 0
- 387 Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.. **2021**, 17, 1389-1396
- 386 Lung cancer risk in never-smokers: An overview of environmental and genetic factors. **2021**, 33, 548-562 2
- 385 Introduction to biomarkers. **2022**, 1-22
- 384 Subclonal landscape of cancer drives resistance to immune therapy.. **2022**, 30, 100507 0
- 383 Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.. **2022**, 164, 69-75 0
- 382 Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.. **2021**, 76, 102080 0
- 381 Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. **2020**, 12, 5505-5516
- 380 Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma.. **2020**, 9, 6683-6690 0
- 379 Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report.. **2021**, 14, 1447-1453 1
- 378 Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data.. **2022**,
- 377 Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer.. **2022**, 7, 9 3
- 376 Circ_0001588 Upregulates ERBB4 to Promote Glioma Malignant Progression Through Sponging miR-1281.. **2022**, 40, 89 0
- 375 Cell-free DNA analysis in current cancer clinical trials: a review.. **2022**, 9
- 374 El cãncer de pulmã de cãulas no pequeãs en la era de la medicina de precisiã. **2022**, 33, 25-35 0
- 373 Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR Mutants.. **2022**, 13, 196-202 0
- 372 Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. **2022**, 27, 5
- 371 Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines.. **2022**, 8, 2

370	FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway.. 2021 , 12, 764699	0
369	Tumor-specific imaging probes in preclinical applications and clinical trials. 2022 , 49-138	
368	Influence Factors of Gefitinib Concentration in Patients with Non-Small Cell Lung Cancer in Clinical Treatment. 2022 , 12, 196-205	0
367	Targeting S100A9-ALDH1A1-retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer.. 2022 ,	2
366	Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA.. 2022 ,	0
365	Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.. 2022 , 14,	1
364	Effects of EGFR gene mutation on stage 3A lung adenocarcinomas in the clinical decision-making process for mediastinal invasive staging. 2022 , 9, 44-49	
363	A scientometric study on quantitative microbial risk assessment in water quality analysis across 6 years (2016-2021).	1
362	Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.. 2022 , 6, e2100232	1
361	Computational Methods for the Analysis and Prediction of EGFR-mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects.. 2022 , PP,	0
360	Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer.. 2021 , 9, 789030	2
359	Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.. 2022 , 12, 972	0
358	Integration of heterogeneous biological data in multiscale mechanistic model calibration: application to lung adenocarcinoma.	1
357	A Retrospective Statistical Validation Approach for Panel of Normal-Based Single-Nucleotide Variant Detection in Tumor Sequencing.. 2022 , 24, 41-47	
356	FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF- κ B Signaling Pathway in -Mutant NSCLC Cells.. 2022 , 20,	1
355	Quantification of single-strand DNA lesions caused by the topoisomerase II poison etoposide using single DNA molecule imaging.. 2022 , 594, 57-62	0
354	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. 2021 ,	0
353	Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.. 2022 , 120, 105605	1

352	Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas. 79,	3
351	A sensitive and selective SNV detection strategy based on non-canonical dsDNA structure preference of endonuclease IV. 2022 , 131575	0
350	Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.. 2022 , 12, 804212	1
349	Role and mechanism of action of LAPTM4B in EGFR-mediated autophagy.. 2022 , 23, 109	0
348	Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor.. 2022 ,	1
347	Tertiary lymphoid structure and decreased CD8 T' cell infiltration in minimally invasive adenocarcinoma.. 2022 , 25, 103883	0
346	Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.. 2022 , 23,	0
345	Liquid Biopsy, Diagnostic Imaging, and Future Synergies.. 2022 , 19, 336-343	1
344	Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.. 2022 , 38, 110343	1
343	Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort.. 2022 ,	2
342	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.. 2022 , 12, 843299	0
341	Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation.. 2022 ,	1
340	The management of postoperative recurrence of non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutation: what is the best way?. 2022 , 14, 812-815	
339	Molecular Imaging Precision Medicine. 2022 , 79-92	
338	Neurological complications of lung cancer. 2022 , 243-276	
337	Conformation-tunable ATP-competitive kinase inhibitors.. 2022 ,	0
336	Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.. 2022 , 21, 15347354221086663	0
335	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.. 2022 , 6, 11	0

- 334 EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription.. **2022,** 0
- 333 Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.. **2022,** 1
- 332 A Retrospective Study of the Utility of the OncoPrint Dx Target Test in Clinical Practice. **2022,** 62, 26-32
- 331 Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. **2022,** 21, 61 0
- 330 Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.. **2022,** 17, e0264201 0
- 329 Tensor decomposition based on the potential low-rank and [Formula: see text]-shrinkage generalized threshold algorithm for analyzing cancer multiomics data.. **2022,** 2250002
- 328 MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumorigenesis.. **2022,** 14, 0
- 327 Elevated nuclear localization of glycolytic enzyme TPI1 promotes lung adenocarcinoma and enhances chemoresistance.. **2022,** 13, 205 0
- 326 In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.
- 325 Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERBB2 expression.. **2022,** 21, 77 3
- 324 Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.. **2022,** 14, 0
- 323 Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma.. **2022,** 213015
- 322 Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.. **2022,** 17, e0264717 2
- 321 Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?. **2022,** 22, 323 1
- 320 Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. 0
- 319 The Frequency of Epidermal Growth Factor Receptor (EGFR) Mutation in Patients with Lung Adenocarcinoma Referred to a Lung Diseases Hospital; A Cross-Sectional Study from Iran.. **2022,** 17, 159-165
- 318 Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. **2022,** 12, 869672 3
- 317 Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease.. **2022,** 12, 4

316	Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.. 2022 , 23, 12	0
315	Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth.. 2022 , 23,	0
314	Mutation-Harboring Lung Cancer Cells Produce CLEC11A with Endothelial Trophic and Tumor-Promoting Activities.. 2022 , 14,	0
313	MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.. 2022 , 20, 27	0
312	Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.. 2022 ,	1
311	An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango.. 2022 , 1	0
310	The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.. 2022 , 15,	0
309	Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.. 2022 , 22, 470	
308	Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.. 2022 , 166, 242-249	
307	Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma.. 2022 , 9, 867494	
306	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. 2021 , 21, 1322	1
305	BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level. 2021 ,	1
304	Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.. 2021 , 2, 40	0
303	Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Regulating Oncogenic Signaling Pathways.. 2021 , 9, 796740	1
302	Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. 2021 ,	5
301	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
300	Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. 2021 , 1, 317-333	
299	Amivantamab for the treatment of exon 20 insertion mutant non-small cell lung cancer.. 2021 , 1-14	1

298	The emergence of cancer genomics in diagnosis and precision medicine.. 2021 , 2, 1263-1264	1
297	C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway.. 2021 ,	1
296	LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.. 2022 , 23, 55	
295	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. 2021 , 61, 911-918	
294	Recent Advances in Ovarian Cancer Treatment. 2022 , 81, 23-28	
293	Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.. 2022 , 82, 1589-1602	0
292	Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.. 2022 , 14,	0
291	A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer.. 2022 , 14,	1
290	Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.. 2022 , 12, 6367	1
289	A Hypoxia-Related Signature for Predicting Prognosis, Cellular Processes, Immune Microenvironment and Targeted Compounds in Lung Squamous Cell Carcinoma.. 2022 , 15, 3991-4006	
288	EGFR signaling pathway as therapeutic target in human cancers.. 2022 ,	1
287	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.. 2022 , 12, 780186	1
286	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review.. 2022 , 14,	0
285	Synergistic enhanced rolling circle amplification based on mutS and radical polymerization for single-point mutation DNA detection.. 2022 , 210, 114295	0
284	Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.. 2022 , 237, 114381	0
283	Deregulated signaling networks in lung cancer. 421-442	
282	Table_1.DOCX. 2020 ,	
281	Table_1.xlsx. 2019 ,	

280 Table_1.DOC. 2020,

279 Table_2.DOC. 2020,

278 Image_1.PDF. 2020,

277 Table_1.XLSX. 2020,

276 Table_2.XLSX. 2020,

275 Data_Sheet_1.PDF. 2020,

274 Data_Sheet_2.xlsx. 2020,

273 Data_Sheet_3.pdf. 2020,

272 Data_Sheet_1.PDF. 2019,

271 Data_Sheet_1.zip. 2019,

270 Data_Sheet_1.pdf. 2018,

269 Data_Sheet_1.docx. 2019,

268 Data_Sheet_1.docx. 2020,

267 Presentation_1.pdf. 2018,

266 Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor. **2005**, 11, 397-405

34

265 CRL2 mediates p14ARF N-terminal ubiquitylation degradation to promote non-small cell lung carcinoma progression.. **2022**,

o

264 [Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer ?with Epidermal Growth Factor Receptor Gene Mutation].. **2022**, 25, 183-192

263 Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.. **2022**,

o

262	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.. 2022 , 10, 872729	0
261	EMT, Stemness, and Drug Resistance in Biological Context: A 3D Tumor Tissue/In Silico Platform for Analysis of Combinatorial Treatment in NSCLC with Aggressive KRAS-Biomarker Signatures.. 2022 , 14,	1
260	Variable mutation expression in human cancers: A 'hide-and-seek' mechanism linked to differential MHC-I presentation dynamics.. 2022 ,	
259	Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.. 2022 , 7, 157	0
258	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. 2022 ,	2
257	Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.. 2022 , 13, 2530	0
256	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature.. 2022 , 11,	0
255	P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells.. 2022 , 14,	2
254	Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.. 2022 , 17, e0267362	0
253	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. 2022 , 14,	0
252	Pleural, Pericardial, and Peritoneal Fluids. 2014 , 127-153	2
251	Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. 2004 , 3, 1335-1342	17
250	TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.. 2022 ,	0
249	Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule. 2022 , 13,	0
248	Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.. 2022 ,	0
247	Effect of PPP1R14D gene high expression in lung adenocarcinoma knocked out on proliferation and apoptosis of DMS53 cell.. 2022 ,	0
246	EGFRC797S mutation and fourth-generation EGFR tyrosine kinase inhibitors. 2022 , 689-709	
245	The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer.	

- 244 Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. **2022**, 14, 2613 0
- 243 The Immun-Enhancing and Synergistic Antitumor Efficacy of Linal Polypeptide Combined with EGFR-TKIs for Advanced NSCLC.
- 242 Recognition of BRAF by CDC37 and Reevaluation of the Activation mechanism for the Class 2 BRAF-L597R mutant. 1
- 241 Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma. 0
- 240 Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma. Volume 15, 5181-5196 0
- 239 Critical roles for EGFR and EGFRHER2 clusters in EGF binding of SW620 human carcinoma cells. **2022**, 19, 1
- 238 A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. 0
- 237 The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. **2022**, 9,
- 236 Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine. 9, 0
- 235 Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer. 0
- 234 Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. **2022**, 16, 117955492211032 0
- 233 Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. **2022**, 27, 3844 0
- 232 MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. 1
- 231 A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure-Activity Relationship. 10, 1
- 230 Application of informatics in cancer research and clinical practice: Opportunities and challenges.
- 229 PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. **2022**, 12, 1
- 228 Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer. 13, 0
- 227 Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer. 13, 0

- 226 Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer. **2005**, 65, 226-235 93
- 225 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. **2005**, 4, 101-112 46
- 224 EGFR, NF- κ B and noncoding RNAs in precision medicine. **2022**,
- 223 Prediction of EGFR Mutation Status in Non-small Cell Lung Cancer Based on Ensemble Learning. 13,
- 222 Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant. **2022**, 12, 905
- 221 Fbxo45-mediated NP-STEP 46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer. 0
- 220 Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program. **2022**, 0
- 219 MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state. 1
- 218 Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
- 217 PM-Search: State-of-the-art Evidence Retriever for Precision Medicine: Algorithm Development and Validation (Preprint).
- 216 Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer. **2022**, 14, 3430 1
- 215 Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGFR Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. **2022**, 23, 7774
- 214 Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.
- 213 A novel prognostic signature of metastasis-associated genes and personalized therapeutic strategy for lung adenocarcinoma patients. 0
- 212 The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer. **2022**, 13,
- 211 Tumor response to radiotherapy and expression of epidermal growth factor receptor mutation and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement in patients with non-small cell lung cancer. **2022**, 34,
- 210 Integration of Heterogeneous Biological Data in Multiscale Mechanistic Model Calibration: Application to Lung Adenocarcinoma. **2022**, 70,
- 209 Novel anilinopyrimidine derivatives as potential EGFR T790M/C797S Inhibitors: Design, Synthesis, biological activity study. **2022**, 70, 116907 0

208	Highly sensitive detection of EGFR L858R mutation at the mRNA level. 2022 , 654, 114799	
207	Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer. 2005 , 65, 338-348	66
206	Cellular Targets of Gefitinib. 2005 , 65, 379-382	61
205	The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non-Small Cell Lung Cancers. 2005 , 11, 1167-1173	87
204	A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter. 2005 , 65, 46-53	33
203	Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. 2015 , 44, 449-462	2
202	A Ferroptosis-Related Gene Signature for Overall Survival Prediction and Immune Infiltration in Lung Squamous Cell Carcinoma.	0
201	Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report.	
200	The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients. 2022 , 1-7	
199	Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC. 2022 , 109, 102438	1
198	Emerging Role of Structural and Systems Biology in Anticancer Therapeutics. 2022 , 97-114	
197	Lazertinib: on the Way to Its Throne. 2022 , 63, 799	0
196	Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion. 12,	0
195	Overexpression of 14-3-3 β primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. 2022 , 14, 5838-5854	1
194	Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma. 2022 , 14, 3671	
193	CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells. 2022 , 14, 3672	
192	Cancer: Immunology and Immunotherapy. 2022 , 159-164	
191	Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. 2022 ,	0

190	Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. 2022,	1
189	Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.	
188	Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets. 2022, 13,	1
187	Panel Sequencing for Targeted Therapy Selection in Solid Tumors. 2022,	
186	Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab. 2022,	0
185	Advances in covalent drug discovery.	9
184	Label-free visualization of cellular response to molecularly targeted agents using multiplex CARS and THG (coherent anti-Stokes Raman scattering and third harmonic generation) microscopy.	
183	FOXA1 prevents nutrients deprivation induced autophagic cell death through inducing loss of imprinting of IGF2 in lung adenocarcinoma. 2022, 13,	1
182	Impact of LncRNA GAS5 Genetic Variants and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma Patients. 2022, 19, 9971	
181	PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug. 2022, 237, 154065	0
180	Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. 2022, 626, 156-166	
179	Epidermal Growth Factor Receptor Gene Polymorphisms Predict Pelvic Recurrence in Patients with Rectal Cancer Treated with Chemoradiation. 2005, 11, 600-605	13
178	The Evolution of Antibodies into Versatile Tumor-Targeting Agents. 2005, 11, 129-138	7
177	Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH. 2022, 18, e1010362	2
176	Control of cell metabolism by the epidermal growth factor receptor. 2022, 1869, 119359	1
175	Therapeutic Schedule of EGFR Mutation in Non-Small Cell Lung Cancer and Review of Health Insurance Policy. 2022, 12, 174-183	0
174	SNPs and Personalized Medicine: Scrutinizing Pathogenic Synonymous Mutations for Precision Oncology. 2022, 185-195	0
173	EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway: A nationwide retrospective cohort study. 2022, 33, 100636	0

172	Switching from ultrafast electron transfer to proton transfer in excited drug-protein complexes upon biotransformation. 2022 , 13, 9644-9654	0
171	Targeted Therapies in Non-small Cell Lung Cancer. 2022 ,	1
170	Genomic Alterations in Lung Cancer. 2022 ,	0
169	EGFR-Targeted Quinazoline Clubbed Heterocycles as Anticancer Agents. 2022 , 387-399	0
168	On the way for the best imaging features from CT images to predict EGFR Mutation Status in Lung Cancer. 2022 ,	0
167	Personalized prediction of response to smartphone-delivered meditation training: A machine learning approach (Preprint).	0
166	Chapter 21: Oncology: Rasburicase/G6PD Case. 2022 ,	0
165	Abbreviations. 2022 ,	0
164	Chapter 29: Pharmacogenomics in Ethical and Social Contexts. 2022 ,	0
163	Appendix 2: Glossary. 2022 ,	0
162	Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/CYP2D6 Case. 2022 ,	0
161	Chapter 8: Cardiology: Simvastatin/SLCO1B1 Case. 2022 ,	0
160	Chapter 28: Information Resources for Pharmacogenomics. 2022 ,	0
159	Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. 2022 ,	0
158	Chapter 17: Neurology: Fosphenytoin/Phenytoin/CYP2C9, HLA-B Case. 2022 ,	0
157	Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. 2022 ,	0
156	Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/HLA-B Case. 2022 ,	0
155	Chapter 12: Infectious Diseases: Abacavir/HLA-B Case. 2022 ,	0

154	Chapter 15: Infectious Diseases: Gentamicin/MT-RNR1 Case. 2022,	0
153	Pharmacogenomics: Foundations, Competencies, and the Pharmacists' Patient Care Process, 2nd Edition. 2022,	0
152	Chapter 13: Infectious Diseases: Atazanavir/UGT1A1 Case. 2022,	0
151	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. 2022,	0
150	Chapter 16: Neurology: Carbamazepine/HLA-A, HLA-B Case. 2022,	0
149	Dedication. 2022,	0
148	Chapter 3: Pharmacogenomics Testing. 2022,	0
147	Structural analysis of the macrocyclic inhibitor BI-4020 binding to EGFR kinase.	0
146	Chapter 24: Metabolic/Respiratory: Ivacaftor/CFTR Case. 2022,	0
145	Chapter 23: Psychiatry: Paroxetine/CYP2D6 Case. 2022,	0
144	Copyright. 2022,	0
143	Chapter 2: Pharmacogenomics: Drug Exposure and Response. 2022,	0
142	Chapter 22: Psychiatry: Amitriptyline/CYP2C19, CYP2D6 Case. 2022,	0
141	Chapter 6: The Pharmacists' Patient Care Process (PPCP). 2022,	0
140	Evolving Experimental Techniques for Structure-Based Drug Design. 2022, 126, 6599-6607	1
139	Chapter 10: Endocrinology: Glipizide/G6PD Case. 2022,	0
138	Chapter 1: Foundations of Pharmacogenomics. 2022,	0
137	Chapter 20: Oncology: Capecitabine/DYPD Case. 2022,	0

- 136 Preface. **2022,** ○
- 135 Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case. **2022,** ○
- 134 Chapter 19: Oncology: Mercaptopurine/TPMT, NUDT15 Case. **2022,** ○
- 133 Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. **2022,** ○
- 132 Chapter 4: Pharmacists' Competencies in Genomics. **2022,** ○
- 131 Appendix 1: Competency Connections. **2022,** ○
- 130 Chapter 5: Implementation of Pharmacogenomics across Practice Settings. **2022,** ○
- 129 Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, NUDT15; Celecoxib/CYP2C9 Case. **2022,** ○
- 128 Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. **2022,** ○
- 127 Development and characterization of reference materials for EGFR, KRAS, NRAS, BRAF, PIK3CA, ALK, and MET genetic testing. **2022,** 1-11 ○
- 126 Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations. **2022,** 22, ○
- 125 Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC. **2022,** 12, 2360 ○
- 124 Utilization of cytologic cell blocks for targeted sequencing of solid tumors. ○
- 123 Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma. **2022,** 11, 2924 ○
- 122 Drug-induced liver injury associated with dacomitinib: A case report. 12, ○
- 121 Genetic alterations shaping tumor response to anti-EGFR therapies. **2022,** 64, 100863 ○
- 120 Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models. **2022,** 39, ○
- 119 Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update. ○

118	A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma.	0
117	Genomic landscape of lung adenocarcinomas in different races. 12,	0
116	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. 2022, 14,	0
115	Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations. 12,	1
114	Evolution of precision oncology-guided treatment paradigms.	0
113	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. 2022, 7,	0
112	Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. 2022, 106188	1
111	Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.	0
110	Predicting Anti-Cancer Drug Combination Responses with a Temporal Cell State Network Model.	0
109	The issues and challenges with cancer biomarkers. 2022, 0	0
108	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. 2022, 251-267	0
107	Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone. 2022, 7,	0
106	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
105	Cancer Genomics and Evolution. 1-30	0
104	Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response.	0
103	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. 2022, 15,	1
102	State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium´ IV.	0
101	Cancer Epidemiology. 1-12	0

100	Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface.	3
99	Aberrant Signaling Pathways in Cancer. 1-10	○
98	The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.	○
97	Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. 2022 , 12, 1651	○
96	Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients: An overview. 12,	○
95	Systems Biology and Genomics. 1-11	○
94	Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFR T790M/L858R inhibitors to treat non-small cell lung cancer. 2022 , 74, 117052	○
93	AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models. 2022 , 156, 113942	○
92	Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. 2022 , 244, 114856	○
91	Invasive Adenocarcinoma Versus Adenocarcinoma In Situ. 2022 , 31-37	○
90	Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. 2022 ,	○
89	Structure-based modification of ortho-amidophenylaminopyrimidines as a novel mutant EGFR inhibitor against resistant non-small cell lung cancer. 2023 , 1274, 134499	○
88	The Latest Information on Chemotherapy for Patients with Advanced Lung Cancer. 2021 , 110, 2441-2448	○
87	PM-Search: State-of-the-art Evidence Retriever for Precision Medicine: Algorithm Development and Validation (Preprint).	○
86	Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).	○
85	Changes in survival of patients with non-small cell lung cancer in Japan: an interrupted time series study.	○
84	A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. 2022 , 13,	○
83	Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.	○

82	Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR. 2023 , 38, 239-245	1
81	The past, present, and future of chemotherapy with a focus on individualization of drug dosing. 2022 , 352, 840-860	2
80	Molecular Biomarkers at the Interface of Basic and Clinical Dengue Research. 2013 , 42, 608-610	1
79	Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. 2022 , 14, 175883592211440	0
78	Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. 2022 , 22,	0
77	Database of recurrent mutations (DORM), a web tool to browse recurrent mutations in cancers.	0
76	Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.	0
75	Glucocorticoid receptor and RAS: an unexpected couple in cancer. 2022 ,	0
74	The Simon's two-stage design accounting for genetic heterogeneity. 1-9	0
73	Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).	0
72	Phytochemicals from <i>Allium tuberosum</i> Rottler ex Spreng Show Potent Inhibitory Activity against B-Raf, EGFR, K-Ras, and PI3K of Non-Small Cell Lung Cancer Targets. 2022 , 12, 11749	1
71	Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer. 2022 ,	0
70	The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer. 12,	0
69	PROTAC therapy as a new targeted therapy for lung cancer. 2022 ,	0
68	Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). 2022 , 22,	0
67	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. 2022 ,	0
66	Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. 2022 , 25,	0
65	Macrophage renewal modes affect acquired resistance to gefitinib in EGFR-mutant lung cancer PC-9 cells. 2022 , 49,	0

64	Identification and validation of critical genes with prognostic value in gastric cancer. 10,	0
63	Reversible Drug Resistance Mechanisms in Non-small Cell Lung Cancer. 2022 , 142, 1321-1326	0
62	A narrative review of cancer molecular diagnostics: past, present, and future. Publish Ahead of Print,	0
61	Deep-Learning Algorithm and Concomitant Biomarker Identification for NSCLC Prediction Using Multi-Omics Data Integration. 2022 , 12, 1839	0
60	Clinical impact of histologic type on survival and recurrence in patients with surgically resected stage II and III non-small cell lung cancer. 2022 ,	0
59	Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq.	0
58	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. 2022 , 15,	1
57	Predicting Tumor Mutation Burden and EGFR Mutation Using Clinical and Radiomic Features in Patients with Malignant Pulmonary Nodules. 2023 , 13, 16	1
56	Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. 2023 , 15, 504	1
55	Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. 2023 , 216062	0
54	Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy.	0
53	Lung adenocarcinoma with neuroendocrine differentiation: Molecular markers testing and treatment outcomes. 2022 ,	0
52	Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody. 2023 , 15, 111	0
51	Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives. 2023 , 16, 43	0
50	Molecular Pathology of Lung Tumors. 2021 , 633-669	0
49	FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. 29,	0
48	Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology. 2023 , 47-62	0
47	Synthesis, Molecular Dynamics Simulation, and In-vitro Antitumor Activity of Quinazoline-2,4,6-triamine Derivatives as Novel EGFR Tyrosine Kinase Inhibitors. 2023 , 21,	0

- 46 Historical development of EGFR-targeted therapy. **2023**, 1-11 ○
- 45 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. **2023**, 13-27 ○
- 44 PLGA-PEI nanobubbles carrying PDLIM5 siRNA inhibit EGFR-TKI-resistant NSCLC cell migration and invasion ability using UTND technology. **2023**, 82, 104346 ○
- 43 Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib. ○
- 42 Digital ECMT Cancer Trial Matching Tool: an Open Source Research Application to Support Oncologists in the Identification of Precision Medicine Clinical Trials. **2023**, ○
- 41 Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer. **2023**, 13, 210 ○
- 40 Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. **2023**, 29, 3-8 ○
- 39 A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. **2023**, 177, 44-50 ○
- 38 6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells. **2023**, 24, 2639 ○
- 37 Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Volume 14, 11-25 ○
- 36 Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. **2023**, 11, 6 ○
- 35 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 34 Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer. **2023**, 651, 39-46 ○
- 33 Liquid Biopsy for Oral Cancer Diagnosis: Recent Advances and Challenges. **2023**, 13, 303 ○
- 32 Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment. **2023**, 10, ○
- 31 Biochemistry Not Oncogenes May Demystify and Defeat Cancer. ○
- 30 Trans-activating mutations of the pseudokinase ERBB3. ○
- 29 Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors. **2023**, 38, 100888 ○

- 28 Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. **2023**, 24, 4126 ○
- 27 Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. **2023**, 13, ○
- 26 The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases. 13, ○
- 25 An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1. ○
- 24 A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. **2023**, 12, 1936 ○
- 23 Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. ○
- 22 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178 ○
- 21 Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study. ○
- 20 A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. **2023**, 8, 101183 ○
- 19 Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality. **2023**, 13, ○
- 18 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32 ○
- 17 Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications. **2023**, 184, 103966 ○
- 16 Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations. **2023**, 70, 41-53 ○
- 15 Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents. **2023**, 85, 117241 ○
- 14 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 ○
- 13 Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. **2023**, 24, 5821 ○
- 12 CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. **2023**, 23, ○
- 11 EBUS-TBNA of a Left Lower Paratracheal Node (Level 4' L) in a Patient with a Left Upper Lobe Lung Mass and Suspected Lung Cancer. **2012**, 207-218 ○

- 10 Mechanism exploration and prognosis study of Astragali Radix-Spreading hedyotis herb for the treatment of lung adenocarcinoma based on bioinformatics approaches and molecular dynamics simulation. 11, ○
- 9 Efficient and environmentally friendly synthesis of 1,2,3-triazole derivatives via [3 + 2] cycloaddition and their potential as lung cancer inhibitors: An in silico study. **2023**, 5, 100903 ○
- 8 Artificial intelligence in healthcare: a mastery. 1-50 ○
- 7 Cancer Cell-Specific Fluorescent Prodrug Delivery Platforms. ○
- 6 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14, ○
- 5 Accelerating the understanding of cancer biology through the lens of genomics. **2023**, 186, 1755-1771 ○
- 4 Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management. ○
- 3 A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy. **2023**, 27, 337-347 ○
- 2 Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells. **2023**, 108466 ○
- 1 An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients. ○